drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB11581 | DB11979 | 1,456 | 1,320 | [
"DDInter1926",
"DDInter625"
] | Venetoclax | Elagolix | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain . It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801]. In particular, estimates suggest that one in ten women of reproductive age is affected by endometriosis and experience debilitating pain symptoms [A35868, A35869, F801]. Moreover, women who are affected by this condition can suffer for up to six to ten years and visit multiple physicians before receiving a proper diagnosis [A35868, A35869, F801]. Subsequently, as Orilissa (elagolix) was approved by the FDA under priority review , this expedited new approval gives healthcare professionals another valuable option for treating the potentially unmet needs of women who are affected by endometriosis, depending on their specific type and severity of endometriosis pain. | Moderate | 1 | [
[
[
1456,
24,
1320
]
],
[
[
1456,
64,
271
],
[
271,
23,
1320
]
],
[
[
1456,
24,
1612
],
[
1612,
23,
1320
]
],
[
[
1456,
64,
79
],
[
79,
24,
1320
]
],
[
[
1456,
63,
26
],
[
26,
24,
1320
]
],
[
[
1456,
25,
913
],
[
913,
24,
1320
]
],
[
[
1456,
24,
484
],
[
484,
63,
1320
]
],
[
[
1456,
24,
1499
],
[
1499,
24,
1320
]
],
[
[
1456,
25,
1043
],
[
1043,
63,
1320
]
],
[
[
1456,
62,
1135
],
[
1135,
24,
1320
]
]
] | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glecaprevir"
],
[
"Glecaprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
]
] | Venetoclax may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Elagolix
Venetoclax may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Venetoclax may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Venetoclax may lead to a major life threatening interaction when taken with Glecaprevir and Glecaprevir may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Elagolix |
DB00844 | DB06282 | 314 | 516 | [
"DDInter1257",
"DDInter1053"
] | Nalbuphine | Levocetirizine | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
314,
24,
516
]
],
[
[
314,
63,
701
],
[
701,
24,
516
]
],
[
[
314,
25,
407
],
[
407,
63,
516
]
],
[
[
314,
40,
421
],
[
421,
24,
516
]
],
[
[
314,
1,
828
],
[
828,
24,
516
]
],
[
[
314,
24,
649
],
[
649,
24,
516
]
],
[
[
314,
25,
593
],
[
593,
24,
516
]
],
[
[
314,
64,
475
],
[
475,
24,
516
]
],
[
[
314,
24,
849
],
[
849,
63,
516
]
],
[
[
314,
63,
701
],
[
701,
23,
771
],
[
771,
62,
516
]
]
] | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} (Compound) resembles {v} (Compound)",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levocetirizine"
]
]
] | Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine |
DB08889 | DB11003 | 350 | 748 | [
"DDInter299",
"DDInter100"
] | Carfilzomib | Anthrax vaccine | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
350,
24,
748
]
],
[
[
350,
63,
168
],
[
168,
24,
748
]
],
[
[
350,
25,
676
],
[
676,
63,
748
]
],
[
[
350,
64,
1057
],
[
1057,
24,
748
]
],
[
[
350,
24,
270
],
[
270,
63,
748
]
],
[
[
350,
24,
1480
],
[
1480,
24,
748
]
],
[
[
350,
25,
375
],
[
375,
24,
748
]
],
[
[
350,
63,
168
],
[
168,
24,
322
],
[
322,
24,
748
]
],
[
[
350,
63,
896
],
[
896,
63,
322
],
[
322,
24,
748
]
],
[
[
350,
25,
676
],
[
676,
64,
322
],
[
322,
24,
748
]
]
] | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
]
] | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB00431 | DB01618 | 1,503 | 776 | [
"DDInter1072",
"DDInter1239"
] | Lindane | Molindone | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment. Lindane is still allowed for pharmaceutical use until 2015. | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283) | Moderate | 1 | [
[
[
1503,
24,
776
]
],
[
[
1503,
21,
28787
],
[
28787,
60,
776
]
],
[
[
1503,
24,
1662
],
[
1662,
63,
776
]
],
[
[
1503,
24,
1264
],
[
1264,
24,
776
]
],
[
[
1503,
63,
999
],
[
999,
24,
776
]
],
[
[
1503,
25,
497
],
[
497,
25,
776
]
],
[
[
1503,
63,
475
],
[
475,
25,
776
]
],
[
[
1503,
24,
1311
],
[
1311,
25,
776
]
],
[
[
1503,
21,
28787
],
[
28787,
60,
1442
],
[
1442,
24,
776
]
],
[
[
1503,
24,
1662
],
[
1662,
24,
407
],
[
407,
63,
776
]
]
] | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Molindone"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
]
] | Lindane (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Molindone (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Lindane may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Molindone
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Molindone
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Molindone
Lindane (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Scopolamine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Molindone |
DB00420 | DB01344 | 508 | 1,231 | [
"DDInter1532",
"DDInter1830"
] | Promazine | Tolevamer | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, HIV. | Moderate | 1 | [
[
[
508,
24,
1231
]
],
[
[
508,
62,
417
],
[
417,
24,
1231
]
],
[
[
508,
40,
1178
],
[
1178,
24,
1231
]
],
[
[
508,
24,
870
],
[
870,
24,
1231
]
],
[
[
508,
24,
603
],
[
603,
63,
1231
]
],
[
[
508,
1,
684
],
[
684,
24,
1231
]
],
[
[
508,
24,
286
],
[
286,
64,
1231
]
],
[
[
508,
23,
1283
],
[
1283,
64,
1231
]
],
[
[
508,
25,
57
],
[
57,
25,
1231
]
],
[
[
508,
62,
417
],
[
417,
62,
1152
],
[
1152,
24,
1231
]
]
] | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
]
] | Promazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Promazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Promazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may lead to a major life threatening interaction when taken with Tolevamer
Promazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may lead to a major life threatening interaction when taken with Tolevamer
Promazine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Tolevamer
Promazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer |
DB04843 | DB11130 | 1,511 | 407 | [
"DDInter1149",
"DDInter1344"
] | Mepenzolate | Opium | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
1511,
24,
407
]
],
[
[
1511,
63,
662
],
[
662,
24,
407
]
],
[
[
1511,
24,
1241
],
[
1241,
24,
407
]
],
[
[
1511,
62,
685
],
[
685,
24,
407
]
],
[
[
1511,
74,
576
],
[
576,
24,
407
]
],
[
[
1511,
40,
649
],
[
649,
24,
407
]
],
[
[
1511,
24,
1536
],
[
1536,
63,
407
]
],
[
[
1511,
64,
306
],
[
306,
24,
407
]
],
[
[
1511,
63,
314
],
[
314,
25,
407
]
],
[
[
1511,
63,
662
],
[
662,
63,
558
],
[
558,
24,
407
]
]
] | [
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
],
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nitroglycerin"
],
[
"Nitroglycerin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
],
[
"Belladonna",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
],
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
]
] | Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole and Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepenzolate may cause a minor interaction that can limit clinical effects when taken with Nitroglycerin and Nitroglycerin may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepenzolate (Compound) resembles Methadone (Compound) and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepenzolate (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Belladonna and Belladonna may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepenzolate may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may lead to a major life threatening interaction when taken with Opium
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Zolpidem and Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB01176 | DB01233 | 537 | 1,311 | [
"DDInter453",
"DDInter1197"
] | Cyclizine | Metoclopramide | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980. | Moderate | 1 | [
[
[
537,
24,
1311
]
],
[
[
537,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
537,
63,
1020
],
[
1020,
24,
1311
]
],
[
[
537,
24,
643
],
[
643,
63,
1311
]
],
[
[
537,
74,
357
],
[
357,
24,
1311
]
],
[
[
537,
24,
1190
],
[
1190,
24,
1311
]
],
[
[
537,
40,
830
],
[
830,
63,
1311
]
],
[
[
537,
64,
306
],
[
306,
24,
1311
]
],
[
[
537,
24,
519
],
[
519,
64,
1311
]
],
[
[
537,
63,
1568
],
[
1568,
25,
1311
]
]
] | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
],
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
],
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
],
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
]
]
] | Cyclizine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Cyclizine (Compound) resembles Benzatropine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Ketamine and Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Cyclizine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Cyclizine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone may lead to a major life threatening interaction when taken with Metoclopramide
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Metoclopramide |
DB01142 | DB04575 | 1,264 | 35 | [
"DDInter593",
"DDInter1555"
] | Doxepin | Quinestrol | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | The 3-cyclopentyl ether of ethinyl estradiol. | Minor | 0 | [
[
[
1264,
23,
35
]
],
[
[
1264,
23,
890
],
[
890,
1,
35
]
],
[
[
1264,
62,
559
],
[
559,
1,
35
]
],
[
[
1264,
63,
752
],
[
752,
23,
35
]
],
[
[
1264,
24,
913
],
[
913,
63,
35
]
],
[
[
1264,
25,
868
],
[
868,
63,
35
]
],
[
[
1264,
24,
392
],
[
392,
24,
35
]
],
[
[
1264,
63,
126
],
[
126,
24,
35
]
],
[
[
1264,
63,
770
],
[
770,
25,
35
]
],
[
[
1264,
23,
890
],
[
890,
1,
1417
],
[
1417,
40,
35
]
]
] | [
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Estrone"
],
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Estramustine"
],
[
"Estramustine",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
]
] | Doxepin may cause a minor interaction that can limit clinical effects when taken with Mestranol and Mestranol (Compound) resembles Quinestrol (Compound)
Doxepin may cause a minor interaction that can limit clinical effects when taken with Estrone and Estrone (Compound) resembles Quinestrol (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinestrol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol
Doxepin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Quinestrol
Doxepin may cause a minor interaction that can limit clinical effects when taken with Mestranol and Mestranol (Compound) resembles Estramustine (Compound) and Estramustine (Compound) resembles Quinestrol (Compound) |
DB00015 | DB00686 | 582 | 383 | [
"DDInter1585",
"DDInter1424"
] | Reteplase | Pentosan polysulfate | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Moderate | 1 | [
[
[
582,
24,
383
]
],
[
[
582,
24,
714
],
[
714,
63,
383
]
],
[
[
582,
25,
405
],
[
405,
63,
383
]
],
[
[
582,
24,
1061
],
[
1061,
24,
383
]
],
[
[
582,
25,
834
],
[
834,
24,
383
]
],
[
[
582,
64,
1578
],
[
1578,
24,
383
]
],
[
[
582,
24,
714
],
[
714,
63,
20
],
[
20,
24,
383
]
],
[
[
582,
25,
405
],
[
405,
64,
714
],
[
714,
63,
383
]
],
[
[
582,
25,
1213
],
[
1213,
21,
28898
],
[
28898,
60,
383
]
],
[
[
582,
25,
936
],
[
936,
63,
714
],
[
714,
63,
383
]
]
] | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
],
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
]
] | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Reteplase may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Reteplase may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Reteplase may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Reteplase may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pentosan polysulfate (Compound)
Reteplase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate |
DB01088 | DB01324 | 714 | 178 | [
"DDInter908",
"DDInter1490"
] | Iloprost | Polythiazide | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
714,
24,
178
]
],
[
[
714,
63,
674
],
[
674,
40,
178
]
],
[
[
714,
63,
126
],
[
126,
23,
178
]
],
[
[
714,
63,
848
],
[
848,
24,
178
]
],
[
[
714,
24,
1450
],
[
1450,
63,
178
]
],
[
[
714,
24,
222
],
[
222,
24,
178
]
],
[
[
714,
63,
674
],
[
674,
40,
504
],
[
504,
40,
178
]
],
[
[
714,
63,
504
],
[
504,
1,
674
],
[
674,
40,
178
]
],
[
[
714,
63,
126
],
[
126,
23,
674
],
[
674,
40,
178
]
],
[
[
714,
63,
848
],
[
848,
63,
674
],
[
674,
40,
178
]
]
] | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
]
]
] | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide (Compound) resembles Polythiazide (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound) |
DB00477 | DB01211 | 216 | 609 | [
"DDInter363",
"DDInter393"
] | Chlorpromazine | Clarithromycin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
216,
24,
609
]
],
[
[
216,
6,
4973
],
[
4973,
45,
609
]
],
[
[
216,
7,
8733
],
[
8733,
57,
609
]
],
[
[
216,
21,
28662
],
[
28662,
60,
609
]
],
[
[
216,
63,
600
],
[
600,
23,
609
]
],
[
[
216,
24,
222
],
[
222,
23,
609
]
],
[
[
216,
23,
752
],
[
752,
23,
609
]
],
[
[
216,
24,
770
],
[
770,
24,
609
]
],
[
[
216,
24,
1383
],
[
1383,
63,
609
]
],
[
[
216,
63,
322
],
[
322,
24,
609
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) upregulates {v} (Gene)",
"PHGDH"
],
[
"PHGDH",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
],
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
]
] | Chlorpromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Chlorpromazine (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Clarithromycin (Compound)
Chlorpromazine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB00991 | DB13074 | 97 | 877 | [
"DDInter1358",
"DDInter1110"
] | Oxaprozin | Macimorelin | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Moderate | 1 | [
[
[
97,
24,
877
]
],
[
[
97,
63,
1479
],
[
1479,
24,
877
]
],
[
[
97,
24,
1662
],
[
1662,
24,
877
]
],
[
[
97,
1,
1236
],
[
1236,
24,
877
]
],
[
[
97,
40,
307
],
[
307,
24,
877
]
],
[
[
97,
24,
477
],
[
477,
25,
877
]
],
[
[
97,
40,
576
],
[
576,
25,
877
]
],
[
[
97,
63,
1555
],
[
1555,
25,
877
]
],
[
[
97,
1,
371
],
[
371,
25,
877
]
],
[
[
97,
25,
39
],
[
39,
25,
877
]
]
] | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} (Compound) resembles {v} (Compound)",
"Methadone"
],
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} (Compound) resembles {v} (Compound)",
"Propafenone"
],
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
]
] | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Oxaprozin (Compound) resembles Carbamazepine (Compound) and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Oxaprozin (Compound) resembles Modafinil (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Macimorelin
Oxaprozin (Compound) resembles Methadone (Compound) and Methadone may lead to a major life threatening interaction when taken with Macimorelin
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may lead to a major life threatening interaction when taken with Macimorelin
Oxaprozin (Compound) resembles Propafenone (Compound) and Propafenone may lead to a major life threatening interaction when taken with Macimorelin
Oxaprozin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Macimorelin |
DB01068 | DB01142 | 1,565 | 1,264 | [
"DDInter411",
"DDInter593"
] | Clonazepam | Doxepin | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.[FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history in the treatment of the aforementioned medical conditions. Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. Unfortunately | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Moderate | 1 | [
[
[
1565,
24,
1264
]
],
[
[
1565,
24,
401
],
[
401,
24,
1264
]
],
[
[
1565,
63,
832
],
[
832,
24,
1264
]
],
[
[
1565,
24,
649
],
[
649,
63,
1264
]
],
[
[
1565,
6,
8374
],
[
8374,
45,
1264
]
],
[
[
1565,
21,
29226
],
[
29226,
60,
1264
]
],
[
[
1565,
1,
1563
],
[
1563,
24,
1264
]
],
[
[
1565,
1,
1418
],
[
1418,
63,
1264
]
],
[
[
1565,
64,
475
],
[
475,
24,
1264
]
],
[
[
1565,
24,
1404
],
[
1404,
64,
1264
]
]
] | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Sinusitis"
],
[
"Sinusitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Halazepam"
],
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} (Compound) resembles {v} (Compound)",
"Estazolam"
],
[
"Estazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flumazenil"
],
[
"Flumazenil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
]
] | Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Clonazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxepin (Compound)
Clonazepam (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Doxepin (Compound)
Clonazepam (Compound) resembles Halazepam (Compound) and Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Clonazepam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Clonazepam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Flumazenil and Flumazenil may lead to a major life threatening interaction when taken with Doxepin |
DB00106 | DB01236 | 618 | 679 | [
"DDInter4",
"DDInter1664"
] | Abarelix | Sevoflurane | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures. | Moderate | 1 | [
[
[
618,
24,
679
]
],
[
[
618,
24,
1262
],
[
1262,
40,
679
]
],
[
[
618,
23,
112
],
[
112,
23,
679
]
],
[
[
618,
24,
484
],
[
484,
63,
679
]
],
[
[
618,
24,
1133
],
[
1133,
24,
679
]
],
[
[
618,
25,
1154
],
[
1154,
64,
679
]
],
[
[
618,
25,
11
],
[
11,
25,
679
]
],
[
[
618,
24,
1487
],
[
1487,
64,
679
]
],
[
[
618,
24,
1262
],
[
1262,
21,
28862
],
[
28862,
60,
679
]
],
[
[
618,
23,
112
],
[
112,
62,
1262
],
[
1262,
40,
679
]
]
] | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
"Perflutren",
"{u} (Compound) resembles {v} (Compound)",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
"Perflutren",
"{u} (Compound) causes {v} (Side Effect)",
"Ventricular tachycardia"
],
[
"Ventricular tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Perflutren"
],
[
"Perflutren",
"{u} (Compound) resembles {v} (Compound)",
"Sevoflurane"
]
]
] | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sevoflurane
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Sevoflurane
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Sevoflurane
Abarelix may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Sevoflurane
Abarelix may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Sevoflurane
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Sevoflurane
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) causes Ventricular tachycardia (Side Effect) and Ventricular tachycardia (Side Effect) is caused by Sevoflurane (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound) |
DB01110 | DB01591 | 86 | 667 | [
"DDInter1209",
"DDInter1696"
] | Miconazole | Solifenacin | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
86,
24,
667
]
],
[
[
86,
6,
8374
],
[
8374,
45,
667
]
],
[
[
86,
21,
29429
],
[
29429,
60,
667
]
],
[
[
86,
24,
392
],
[
392,
24,
667
]
],
[
[
86,
64,
1557
],
[
1557,
24,
667
]
],
[
[
86,
24,
1342
],
[
1342,
63,
667
]
],
[
[
86,
62,
1101
],
[
1101,
24,
667
]
],
[
[
86,
63,
1424
],
[
1424,
24,
667
]
],
[
[
86,
63,
11
],
[
11,
25,
667
]
],
[
[
86,
24,
39
],
[
39,
64,
667
]
]
] | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Solifenacin"
]
]
] | Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Miconazole (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Solifenacin (Compound)
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Miconazole may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Miconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Solifenacin
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Solifenacin |
DB00798 | DB01050 | 1,132 | 848 | [
"DDInter815",
"DDInter900"
] | Gentamicin | Ibuprofen | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer. | Moderate | 1 | [
[
[
1132,
24,
848
]
],
[
[
1132,
6,
10612
],
[
10612,
45,
848
]
],
[
[
1132,
21,
28929
],
[
28929,
60,
848
]
],
[
[
1132,
63,
831
],
[
831,
24,
848
]
],
[
[
1132,
24,
242
],
[
242,
63,
848
]
],
[
[
1132,
62,
664
],
[
664,
24,
848
]
],
[
[
1132,
25,
1680
],
[
1680,
24,
848
]
],
[
[
1132,
24,
935
],
[
935,
24,
848
]
],
[
[
1132,
64,
1028
],
[
1028,
24,
848
]
],
[
[
1132,
35,
416
],
[
416,
63,
848
]
]
] | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
],
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Perindopril"
],
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
],
[
"Kanamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
]
] | Gentamicin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Ibuprofen (Compound)
Gentamicin (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Ibuprofen (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Gentamicin may cause a minor interaction that can limit clinical effects when taken with Perindopril and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Gentamicin may lead to a major life threatening interaction when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Gentamicin may lead to a major life threatening interaction when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Gentamicin (Compound) resembles Kanamycin (Compound) and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin and Kanamycin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen |
DB00489 | DB12267 | 17 | 1,476 | [
"DDInter1704",
"DDInter233"
] | Sotalol | Brigatinib | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376] | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
17,
24,
1476
]
],
[
[
17,
25,
918
],
[
918,
24,
1476
]
],
[
[
17,
63,
176
],
[
176,
24,
1476
]
],
[
[
17,
64,
79
],
[
79,
24,
1476
]
],
[
[
17,
23,
578
],
[
578,
24,
1476
]
],
[
[
17,
24,
1559
],
[
1559,
24,
1476
]
],
[
[
17,
25,
982
],
[
982,
63,
1476
]
],
[
[
17,
1,
88
],
[
88,
24,
1476
]
],
[
[
17,
25,
129
],
[
129,
25,
1476
]
],
[
[
17,
64,
600
],
[
600,
25,
1476
]
]
] | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
]
] | Sotalol may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sotalol may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sotalol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sotalol may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sotalol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sotalol may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib
Sotalol may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Brigatinib |
DB01097 | DB01101 | 1,377 | 60 | [
"DDInter1033",
"DDInter285"
] | Leflunomide | Capecitabine | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Major | 2 | [
[
[
1377,
25,
60
]
],
[
[
1377,
6,
6017
],
[
6017,
45,
60
]
],
[
[
1377,
21,
28906
],
[
28906,
60,
60
]
],
[
[
1377,
64,
1176
],
[
1176,
23,
60
]
],
[
[
1377,
25,
309
],
[
309,
62,
60
]
],
[
[
1377,
63,
112
],
[
112,
24,
60
]
],
[
[
1377,
25,
713
],
[
713,
63,
60
]
],
[
[
1377,
64,
599
],
[
599,
24,
60
]
],
[
[
1377,
24,
1430
],
[
1430,
63,
60
]
],
[
[
1377,
62,
1461
],
[
1461,
24,
60
]
]
] | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Gastroenteritis"
],
[
"Gastroenteritis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
]
] | Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Capecitabine (Compound)
Leflunomide (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Capecitabine (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Leflunomide may lead to a major life threatening interaction when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Leflunomide may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Leflunomide may lead to a major life threatening interaction when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine |
DB00741 | DB12500 | 167 | 283 | [
"DDInter885",
"DDInter714"
] | Hydrocortisone | Fedratinib | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
167,
24,
283
]
],
[
[
167,
24,
351
],
[
351,
23,
283
]
],
[
[
167,
63,
122
],
[
122,
23,
283
]
],
[
[
167,
63,
1419
],
[
1419,
24,
283
]
],
[
[
167,
24,
336
],
[
336,
24,
283
]
],
[
[
167,
25,
932
],
[
932,
24,
283
]
],
[
[
167,
25,
676
],
[
676,
63,
283
]
],
[
[
167,
1,
891
],
[
891,
24,
283
]
],
[
[
167,
23,
1072
],
[
1072,
24,
283
]
],
[
[
167,
40,
870
],
[
870,
24,
283
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
]
] | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Hydrocortisone may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Hydrocortisone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Hydrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Isoniazid and Isoniazid may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib |
DB00328 | DB00927 | 831 | 1,559 | [
"DDInter921",
"DDInter712"
] | Indomethacin | Famotidine | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlorobenzoyl)25-methoxy-2-methylindole-3-acetic acid. The pharmacological effect of indometacin is not fully understood, however, it is thought to be mediated through potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via the arachidonic acid (AA) pathway. Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings. | Minor | 0 | [
[
[
831,
23,
1559
]
],
[
[
831,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
831,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
831,
40,
24
],
[
24,
23,
1559
]
],
[
[
831,
23,
1384
],
[
1384,
62,
1559
]
],
[
[
831,
24,
1274
],
[
1274,
23,
1559
]
],
[
[
831,
25,
1468
],
[
1468,
62,
1559
]
],
[
[
831,
24,
848
],
[
848,
62,
1559
]
],
[
[
831,
24,
1555
],
[
1555,
24,
1559
]
],
[
[
831,
25,
39
],
[
39,
63,
1559
]
]
] | [
[
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} (Compound) resembles {v} (Compound)",
"Tolmetin"
],
[
"Tolmetin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
]
] | Indomethacin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Indomethacin (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Indomethacin (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a minor interaction that can limit clinical effects when taken with Famotidine
Indomethacin may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a minor interaction that can limit clinical effects when taken with Famotidine
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Famotidine
Indomethacin may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Famotidine
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Famotidine
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine
Indomethacin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Famotidine |
DB00476 | DB00619 | 109 | 1,419 | [
"DDInter608",
"DDInter909"
] | Duloxetine | Imatinib | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Moderate | 1 | [
[
[
109,
24,
1419
]
],
[
[
109,
6,
12523
],
[
12523,
45,
1419
]
],
[
[
109,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
109,
25,
222
],
[
222,
62,
1419
]
],
[
[
109,
24,
283
],
[
283,
63,
1419
]
],
[
[
109,
63,
305
],
[
305,
24,
1419
]
],
[
[
109,
40,
758
],
[
758,
24,
1419
]
],
[
[
109,
25,
39
],
[
39,
63,
1419
]
],
[
[
109,
25,
506
],
[
506,
24,
1419
]
],
[
[
109,
24,
752
],
[
752,
24,
1419
]
]
] | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} (Compound) resembles {v} (Compound)",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
]
] | Duloxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Imatinib (Compound)
Duloxetine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Duloxetine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Imatinib
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Duloxetine (Compound) resembles Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Duloxetine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Duloxetine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib |
DB00290 | DB09074 | 329 | 1,362 | [
"DDInter219",
"DDInter1327"
] | Bleomycin | Olaparib | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Moderate | 1 | [
[
[
329,
24,
1362
]
],
[
[
329,
24,
896
],
[
896,
24,
1362
]
],
[
[
329,
63,
552
],
[
552,
24,
1362
]
],
[
[
329,
24,
385
],
[
385,
63,
1362
]
],
[
[
329,
23,
839
],
[
839,
24,
1362
]
],
[
[
329,
25,
850
],
[
850,
24,
1362
]
],
[
[
329,
25,
962
],
[
962,
64,
1362
]
],
[
[
329,
64,
1066
],
[
1066,
25,
1362
]
],
[
[
329,
63,
362
],
[
362,
25,
1362
]
],
[
[
329,
25,
1011
],
[
1011,
25,
1362
]
]
] | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
],
[
"Isatuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
],
[
"Bacillus calmette-guerin substrain tice live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
]
] | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab and Isatuximab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bleomycin may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bleomycin may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bleomycin may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Olaparib
Bleomycin may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Olaparib
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Olaparib
Bleomycin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Olaparib |
DB00691 | DB09268 | 1,058 | 1,662 | [
"DDInter1237",
"DDInter1464"
] | Moexipril | Picosulfuric acid | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
1058,
24,
1662
]
],
[
[
1058,
24,
708
],
[
708,
24,
1662
]
],
[
[
1058,
63,
1573
],
[
1573,
24,
1662
]
],
[
[
1058,
40,
1638
],
[
1638,
24,
1662
]
],
[
[
1058,
24,
407
],
[
407,
63,
1662
]
],
[
[
1058,
1,
664
],
[
664,
24,
1662
]
],
[
[
1058,
24,
708
],
[
708,
63,
997
],
[
997,
24,
1662
]
],
[
[
1058,
63,
1573
],
[
1573,
24,
1482
],
[
1482,
23,
1662
]
],
[
[
1058,
63,
912
],
[
912,
24,
484
],
[
484,
63,
1662
]
],
[
[
1058,
40,
1638
],
[
1638,
24,
708
],
[
708,
24,
1662
]
]
] | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Perindopril"
],
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
],
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
]
] | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Moexipril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Moexipril (Compound) resembles Perindopril (Compound) and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Moexipril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid |
DB09083 | DB12500 | 880 | 283 | [
"DDInter996",
"DDInter714"
] | Ivabradine | Fedratinib | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
880,
25,
283
]
],
[
[
880,
25,
351
],
[
351,
23,
283
]
],
[
[
880,
64,
1593
],
[
1593,
23,
283
]
],
[
[
880,
64,
1419
],
[
1419,
24,
283
]
],
[
[
880,
63,
951
],
[
951,
24,
283
]
],
[
[
880,
25,
971
],
[
971,
24,
283
]
],
[
[
880,
24,
98
],
[
98,
24,
283
]
],
[
[
880,
24,
159
],
[
159,
63,
283
]
],
[
[
880,
64,
888
],
[
888,
25,
283
]
],
[
[
880,
24,
1017
],
[
1017,
25,
283
]
]
] | [
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Ivabradine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Ivabradine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Ivabradine may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Ivabradine may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Ivabradine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Fedratinib
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib |
DB09312 | DB11817 | 967 | 1,259 | [
"DDInter103",
"DDInter165"
] | Antilymphocyte immunoglobulin (horse) | Baricitinib | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types. Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022. | Major | 2 | [
[
[
967,
25,
1259
]
],
[
[
967,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
967,
24,
949
],
[
949,
24,
1259
]
],
[
[
967,
24,
1129
],
[
1129,
63,
1259
]
],
[
[
967,
25,
1011
],
[
1011,
25,
1259
]
],
[
[
967,
64,
1064
],
[
1064,
25,
1259
]
],
[
[
967,
25,
779
],
[
779,
64,
1259
]
],
[
[
967,
63,
259
],
[
259,
25,
1259
]
],
[
[
967,
24,
270
],
[
270,
64,
1259
]
],
[
[
967,
24,
1531
],
[
1531,
25,
1259
]
]
] | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
]
] | Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may lead to a major life threatening interaction when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may lead to a major life threatening interaction when taken with Baricitinib |
DB00327 | DB06691 | 421 | 849 | [
"DDInter890",
"DDInter1155"
] | Hydromorphone | Mepyramine | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. Even though hydromorphone does not present a 6-hydroxyl group, it is categorized under the family of phenanthrenes and it is considered a chemical under the schedule II (medical purposes with high addiction potential). The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
421,
24,
849
]
],
[
[
421,
24,
1594
],
[
1594,
24,
849
]
],
[
[
421,
6,
12523
],
[
12523,
45,
849
]
],
[
[
421,
1,
828
],
[
828,
24,
849
]
],
[
[
421,
63,
1648
],
[
1648,
24,
849
]
],
[
[
421,
24,
412
],
[
412,
63,
849
]
],
[
[
421,
40,
993
],
[
993,
24,
849
]
],
[
[
421,
64,
475
],
[
475,
24,
849
]
],
[
[
421,
25,
1053
],
[
1053,
24,
849
]
],
[
[
421,
24,
662
],
[
662,
35,
849
]
]
] | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
],
[
"Diamorphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
]
] | Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Hydromorphone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Hydromorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Hydromorphone (Compound) resembles Diamorphine (Compound) and Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Hydromorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Hydromorphone may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine |
DB01177 | DB06699 | 77 | 774 | [
"DDInter904",
"DDInter493"
] | Idarubicin | Degarelix | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Moderate | 1 | [
[
[
77,
24,
774
]
],
[
[
77,
63,
521
],
[
521,
1,
774
]
],
[
[
77,
21,
29232
],
[
29232,
60,
774
]
],
[
[
77,
62,
112
],
[
112,
23,
774
]
],
[
[
77,
63,
888
],
[
888,
24,
774
]
],
[
[
77,
24,
484
],
[
484,
63,
774
]
],
[
[
77,
24,
1084
],
[
1084,
24,
774
]
],
[
[
77,
62,
739
],
[
739,
24,
774
]
],
[
[
77,
74,
322
],
[
322,
24,
774
]
],
[
[
77,
64,
770
],
[
770,
24,
774
]
]
] | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
],
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
]
] | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Idarubicin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Degarelix
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine and Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Idarubicin (Compound) resembles Epirubicin (Compound) and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Idarubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Degarelix |
DB00372 | DB01174 | 999 | 697 | [
"DDInter1793",
"DDInter1442"
] | Thiethylperazine | Phenobarbital | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
999,
24,
697
]
],
[
[
999,
24,
759
],
[
759,
1,
697
]
],
[
[
999,
63,
362
],
[
362,
1,
697
]
],
[
[
999,
24,
536
],
[
536,
40,
697
]
],
[
[
999,
24,
401
],
[
401,
24,
697
]
],
[
[
999,
24,
516
],
[
516,
63,
697
]
],
[
[
999,
63,
1214
],
[
1214,
24,
697
]
],
[
[
999,
25,
1311
],
[
1311,
63,
697
]
],
[
[
999,
25,
593
],
[
593,
24,
697
]
],
[
[
999,
24,
1374
],
[
1374,
64,
697
]
]
] | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minoxidil"
],
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
]
]
] | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Phenobarbital (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil and Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Thiethylperazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Thiethylperazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may lead to a major life threatening interaction when taken with Phenobarbital |
DB00970 | DB01059 | 0 | 956 | [
"DDInter466",
"DDInter1313"
] | Dactinomycin | Norfloxacin | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
0,
23,
956
]
],
[
[
0,
23,
872
],
[
872,
40,
956
]
],
[
[
0,
62,
1176
],
[
1176,
1,
956
]
],
[
[
0,
23,
1539
],
[
1539,
1,
956
]
],
[
[
0,
6,
5918
],
[
5918,
45,
956
]
],
[
[
0,
18,
3199
],
[
3199,
45,
956
]
],
[
[
0,
21,
28658
],
[
28658,
60,
956
]
],
[
[
0,
24,
1307
],
[
1307,
23,
956
]
],
[
[
0,
63,
377
],
[
377,
23,
956
]
],
[
[
0,
24,
1532
],
[
1532,
62,
956
]
]
] | [
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A5"
],
[
"SLC22A5",
"{u} (Gene) is bound by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} (Compound) downregulates {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is bound by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
"Mitomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
]
] | Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin and Ofloxacin (Compound) resembles Norfloxacin (Compound)
Dactinomycin (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is bound by Norfloxacin (Compound)
Dactinomycin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Norfloxacin (Compound)
Dactinomycin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Norfloxacin (Compound)
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a minor interaction that can limit clinical effects when taken with Norfloxacin |
DB00496 | DB00719 | 194 | 1,219 | [
"DDInter480",
"DDInter149"
] | Darifenacin | Azatadine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. | Moderate | 1 | [
[
[
194,
24,
1219
]
],
[
[
194,
63,
13
],
[
13,
24,
1219
]
],
[
[
194,
24,
830
],
[
830,
1,
1219
]
],
[
[
194,
6,
8374
],
[
8374,
45,
1219
]
],
[
[
194,
24,
543
],
[
543,
63,
1219
]
],
[
[
194,
24,
85
],
[
85,
24,
1219
]
],
[
[
194,
40,
704
],
[
704,
63,
1219
]
],
[
[
194,
35,
262
],
[
262,
63,
1219
]
],
[
[
194,
74,
352
],
[
352,
24,
1219
]
],
[
[
194,
40,
576
],
[
576,
24,
1219
]
]
] | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} (Compound) resembles {v} (Compound)",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound)",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
]
] | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine (Compound) resembles Azatadine (Compound)
Darifenacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Azatadine (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Darifenacin (Compound) resembles Fentanyl (Compound) and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Darifenacin (Compound) resembles Clidinium (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Darifenacin (Compound) resembles Trospium (Compound) and Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Darifenacin (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Azatadine |
DB00626 | DB09134 | 1,441 | 1,552 | [
"DDInter161",
"DDInter966"
] | Bacitracin | Ioversol | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A181997,L7748] | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol, enhances the contrast between vessels in the path of the flow of the contrast medium and normal tissue, allowing the visualization of internal structures. Ioversol is a highly hydrophilic agent considered to be generally safe; however, serious adverse reactions have been reported due to the inadvertent intrathecal administration of ioversol, which is only indicated for intra-arterial and intravenous use. Ioversol was approved by the FDA in 1989 and is currently indicated for computed tomographic (CT) imaging and contrast enhancement in peripheral arteriography, coronary arteriography, and left ventriculography.[L41780,L41790] | Major | 2 | [
[
[
1441,
25,
1552
]
],
[
[
1441,
24,
242
],
[
242,
63,
1552
]
],
[
[
1441,
25,
1448
],
[
1448,
25,
1552
]
],
[
[
1441,
63,
963
],
[
963,
25,
1552
]
],
[
[
1441,
25,
1381
],
[
1381,
64,
1552
]
],
[
[
1441,
24,
372
],
[
372,
25,
1552
]
],
[
[
1441,
40,
1481
],
[
1481,
25,
1552
]
],
[
[
1441,
24,
242
],
[
242,
63,
1648
],
[
1648,
24,
1552
]
],
[
[
1441,
25,
1448
],
[
1448,
24,
242
],
[
242,
63,
1552
]
],
[
[
1441,
63,
963
],
[
963,
24,
848
],
[
848,
25,
1552
]
]
] | [
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Plazomicin"
],
[
"Plazomicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} (Compound) resembles {v} (Compound)",
"Polymyxin B"
],
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
]
] | Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Bacitracin may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin may lead to a major life threatening interaction when taken with Ioversol
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Zoledronic acid and Zoledronic acid may lead to a major life threatening interaction when taken with Ioversol
Bacitracin may lead to a major life threatening interaction when taken with Plazomicin and Plazomicin may lead to a major life threatening interaction when taken with Ioversol
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Ioversol
Bacitracin (Compound) resembles Polymyxin B (Compound) and Polymyxin B may lead to a major life threatening interaction when taken with Ioversol
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Bacitracin may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Zoledronic acid and Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Ioversol |
DB09076 | DB13913 | 1,116 | 1,536 | [
"DDInter1899",
"DDInter175"
] | Umeclidinium | Belladonna | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. Maintenance of the airway is controlled by the parasympathetic nervous system, particularly by the abundance of the muscarinic subtype 3 (M3) in the airway smooth muscle. Parasympathetic ganglia are associated with the larger airways while postganglionic fibers innervate the smaller diameter bronchioles contributing to airway resistance. By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. However, | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as an adjunct for anaesthesia. The name "belladonna" originates from the Italian words "beautiful woman" and the historical use of herb eye-drops by women to dilate the pupils of the eyes for aesthetic purposes. Belladonna is a poisonous plant and belladonna intoxication from accidental ingestion may result in a severe anticholinergic syndrome, which is associated with both central and peripheral manifestations . | Moderate | 1 | [
[
[
1116,
24,
1536
]
],
[
[
1116,
63,
849
],
[
849,
24,
1536
]
],
[
[
1116,
24,
412
],
[
412,
24,
1536
]
],
[
[
1116,
63,
849
],
[
849,
63,
128
],
[
128,
24,
1536
]
],
[
[
1116,
63,
128
],
[
128,
24,
849
],
[
849,
24,
1536
]
],
[
[
1116,
24,
412
],
[
412,
63,
849
],
[
849,
24,
1536
]
],
[
[
1116,
63,
100
],
[
100,
35,
849
],
[
849,
24,
1536
]
],
[
[
1116,
63,
1264
],
[
1264,
74,
1376
],
[
1376,
24,
1536
]
],
[
[
1116,
63,
537
],
[
537,
40,
104
],
[
104,
24,
1536
]
],
[
[
1116,
24,
412
],
[
412,
24,
407
],
[
407,
24,
1536
]
]
] | [
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
]
] | Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine (Compound) resembles Mepyramine (Compound) and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin (Compound) resembles Diphenhydramine (Compound) and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Belladonna |
DB00574 | DB08875 | 121 | 1,618 | [
"DDInter717",
"DDInter262"
] | Fenfluramine | Cabozantinib | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Moderate | 1 | [
[
[
121,
24,
1618
]
],
[
[
121,
24,
1032
],
[
1032,
63,
1618
]
],
[
[
121,
24,
480
],
[
480,
24,
1618
]
],
[
[
121,
25,
41
],
[
41,
63,
1618
]
],
[
[
121,
25,
222
],
[
222,
24,
1618
]
],
[
[
121,
23,
479
],
[
479,
24,
1618
]
],
[
[
121,
64,
529
],
[
529,
24,
1618
]
],
[
[
121,
63,
1324
],
[
1324,
24,
1618
]
],
[
[
121,
24,
885
],
[
885,
25,
1618
]
],
[
[
121,
25,
888
],
[
888,
25,
1618
]
]
] | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
]
] | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Fenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Fenfluramine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may lead to a major life threatening interaction when taken with Cabozantinib
Fenfluramine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Cabozantinib |
DB00559 | DB08895 | 152 | 976 | [
"DDInter223",
"DDInter1825"
] | Bosentan | Tofacitinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Moderate | 1 | [
[
[
152,
24,
976
]
],
[
[
152,
24,
214
],
[
214,
63,
976
]
],
[
[
152,
25,
1017
],
[
1017,
63,
976
]
],
[
[
152,
24,
86
],
[
86,
24,
976
]
],
[
[
152,
62,
608
],
[
608,
24,
976
]
],
[
[
152,
63,
1324
],
[
1324,
24,
976
]
],
[
[
152,
62,
1101
],
[
1101,
25,
976
]
],
[
[
152,
24,
39
],
[
39,
25,
976
]
],
[
[
152,
25,
1377
],
[
1377,
25,
976
]
],
[
[
152,
24,
1480
],
[
1480,
64,
976
]
]
] | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
]
] | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Bosentan may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Tofacitinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Tofacitinib
Bosentan may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tofacitinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Tofacitinib |
DB01276 | DB09100 | 123 | 320 | [
"DDInter706",
"DDInter1799"
] | Exenatide | Thyroid, porcine | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available. | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyroid extract is no longer considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of the tablet. Currently, patients are more likely to be treated with [levothyroxine]. Thyroid extracts were never FDA approved as their use in the United States predates the FDA. | Moderate | 1 | [
[
[
123,
24,
320
]
],
[
[
123,
63,
417
],
[
417,
23,
320
]
],
[
[
123,
63,
1144
],
[
1144,
24,
320
]
],
[
[
123,
24,
1296
],
[
1296,
63,
320
]
],
[
[
123,
24,
22
],
[
22,
24,
320
]
],
[
[
123,
63,
417
],
[
417,
24,
127
],
[
127,
24,
320
]
],
[
[
123,
63,
1144
],
[
1144,
63,
417
],
[
417,
23,
320
]
],
[
[
123,
63,
1445
],
[
1445,
63,
127
],
[
127,
24,
320
]
],
[
[
123,
24,
1296
],
[
1296,
63,
417
],
[
417,
23,
320
]
],
[
[
123,
24,
22
],
[
22,
63,
127
],
[
127,
24,
320
]
]
] | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
]
] | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Thyroid, porcine |
DB00341 | DB01589 | 1,242 | 481 | [
"DDInter343",
"DDInter1552"
] | Cetirizine | Quazepam | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allergic rhinitis_. The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms. Allergic rhinitis is associated with multiple missed or unproductive days at work and school, problems with sleep, and other difficulties with day to day activities for many individuals. Furthermore, some antihistamine agents that are used to treat this condition cause undesirable, sedating effects. Cetirizine is one of the first second-generation H1 antihistamines (SGAHs) formulated to selectively inhibit the H1 receptor | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other receptors. | Moderate | 1 | [
[
[
1242,
24,
481
]
],
[
[
1242,
24,
1216
],
[
1216,
1,
481
]
],
[
[
1242,
63,
905
],
[
905,
40,
481
]
],
[
[
1242,
63,
1174
],
[
1174,
1,
481
]
],
[
[
1242,
21,
28757
],
[
28757,
60,
481
]
],
[
[
1242,
62,
1031
],
[
1031,
23,
481
]
],
[
[
1242,
24,
1532
],
[
1532,
24,
481
]
],
[
[
1242,
24,
407
],
[
407,
63,
481
]
],
[
[
1242,
74,
701
],
[
701,
24,
481
]
],
[
[
1242,
63,
1648
],
[
1648,
24,
481
]
]
] | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorazepam"
],
[
"Lorazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temazepam"
],
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
]
] | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam (Compound) resembles Quazepam (Compound)
Cetirizine (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Quazepam (Compound)
Cetirizine may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Quazepam
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Cetirizine (Compound) resembles Clemastine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Quazepam |
DB00682 | DB05541 | 126 | 801 | [
"DDInter1951",
"DDInter239"
] | Warfarin | Brivaracetam | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Minor | 0 | [
[
[
126,
23,
801
]
],
[
[
126,
23,
477
],
[
477,
23,
801
]
],
[
[
126,
24,
101
],
[
101,
23,
801
]
],
[
[
126,
63,
1215
],
[
1215,
23,
801
]
],
[
[
126,
62,
168
],
[
168,
23,
801
]
],
[
[
126,
64,
600
],
[
600,
23,
801
]
],
[
[
126,
1,
1376
],
[
1376,
24,
801
]
],
[
[
126,
24,
1264
],
[
1264,
24,
801
]
],
[
[
126,
25,
1347
],
[
1347,
24,
801
]
],
[
[
126,
23,
477
],
[
477,
64,
1215
],
[
1215,
23,
801
]
]
] | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
]
] | Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Warfarin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Warfarin (Compound) resembles Diphenhydramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Warfarin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam
Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Brivaracetam |
DB00388 | DB01170 | 1,636 | 1,150 | [
"DDInter1453",
"DDInter846"
] | Phenylephrine | Guanethidine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
1636,
24,
1150
]
],
[
[
1636,
63,
73
],
[
73,
24,
1150
]
],
[
[
1636,
24,
1344
],
[
1344,
63,
1150
]
],
[
[
1636,
1,
874
],
[
874,
24,
1150
]
],
[
[
1636,
24,
1148
],
[
1148,
24,
1150
]
],
[
[
1636,
25,
1264
],
[
1264,
24,
1150
]
],
[
[
1636,
25,
1629
],
[
1629,
63,
1150
]
],
[
[
1636,
25,
290
],
[
290,
25,
1150
]
],
[
[
1636,
37,
247
],
[
247,
76,
1150
]
],
[
[
1636,
63,
73
],
[
73,
6,
7390
],
[
7390,
45,
1150
]
]
] | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound)",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A2"
],
[
"SLC6A2",
"{u} (Gene) is bound by {v} (Compound)",
"Guanethidine"
]
]
] | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Phenylephrine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Phenylephrine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Phenylephrine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Phenylephrine may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Guanethidine
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Phenylephrine may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine and Iobenguane may lead to a major life threatening interaction when taken with Guanethidine
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Guanethidine (Compound) |
DB01144 | DB09564 | 1,326 | 1,296 | [
"DDInter540",
"DDInter930"
] | Diclofenamide | Insulin degludec | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism.[A18561,A18562,A18563,A18564,A174934] Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle.[A18561,A18562,A18563,A18564,A174934] Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.[A18561,A18562,A18563,A18564,A174934] Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.[A18561,A18562,A18563,A18564,A174934] Insulin is an essential treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels.[A18561,A18562,A18563,A18564,A174934] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood.[A18561,A18562,A18563,A18564,A174934] Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels.[A18561,A18562,A18563,A18564,A174934] Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed later in the course of T2D, after several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own.[A18561,A18562,A18563,A18564,A174934] Marketed as the brand name product Tresiba, insulin degludec has a duration of action up to 42 hours allowing for once-daily dosing, typically at bedtime.[A18561,A18562,A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight.[A18561,A18562,A18563,A18564,A174934] Basal insulin is often combined with short-acting "bolus insulin" such as , , or to provide higher doses of insulin required following meals. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with the goal of avoiding any periods of hypoglycemia.[A18561,A18562,A18563,A18564,A174934] Compared to endogenous insulin, insulin degludec has an added hexadecanedioic acid on lysine at the B29 position, allowing for the formation of multi-hexamers.[A18561,A18562,A18563,A18564,A174934] When injected subcutaneously, these multi-hexamers form a drug depot store from which monomers are slowly and continuously absorbed into circulation.[A18561,A18562,A18563,A18564,A174934] As a result, Insulin Degludec has a protracted time action profile due to the delayed absorption from subcutaneous tissue depots into the systemic circulation.[A18561,A18562,A18563,A18564,A174934] Compared to available long-acting analogs such as and , which have a duration of action of 20-24 hours, insulin degludec provides a consistent level of basal insulin over 42 hours with a low peak: trough ratio.[A18561,A18562,A18563,A18564,A174934] Limitations of shorter-acting analogs include more frequent dosing and less stable pharmacokinetics, which may negatively impact patient adherence and glucose control, particularly nocturnal control.[A18561,A18562,A18563,A18564,A174934] Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst.[A18561,A18562,A18563,A18564,A174934] If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.[A18561,A18562,A18563,A18564,A174934] Insulin Degludec was approved by the FDA in September 2015 as the product Tresiba, for use in providing glycemic control to adults with diabetes mellitus. | Moderate | 1 | [
[
[
1326,
24,
1296
]
],
[
[
1326,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
1326,
24,
659
],
[
659,
24,
1296
]
],
[
[
1326,
64,
1645
],
[
1645,
24,
1296
]
],
[
[
1326,
1,
674
],
[
674,
24,
1296
]
],
[
[
1326,
62,
964
],
[
964,
24,
1296
]
],
[
[
1326,
24,
1385
],
[
1385,
63,
1296
]
],
[
[
1326,
40,
504
],
[
504,
24,
1296
]
],
[
[
1326,
63,
1411
],
[
1411,
62,
1103
],
[
1103,
23,
1296
]
],
[
[
1326,
24,
659
],
[
659,
64,
17
],
[
17,
24,
1296
]
]
] | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
]
] | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Diclofenamide may lead to a major life threatening interaction when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Diclofenamide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Diclofenamide may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec |
DB00872 | DB14568 | 1,080 | 982 | [
"DDInter438",
"DDInter1000"
] | Conivaptan | Ivosidenib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Major | 2 | [
[
[
1080,
25,
982
]
],
[
[
1080,
63,
168
],
[
168,
23,
982
]
],
[
[
1080,
62,
1101
],
[
1101,
23,
982
]
],
[
[
1080,
64,
608
],
[
608,
23,
982
]
],
[
[
1080,
25,
976
],
[
976,
24,
982
]
],
[
[
1080,
1,
700
],
[
700,
24,
982
]
],
[
[
1080,
64,
543
],
[
543,
24,
982
]
],
[
[
1080,
63,
1195
],
[
1195,
24,
982
]
],
[
[
1080,
25,
159
],
[
159,
63,
982
]
],
[
[
1080,
24,
973
],
[
973,
24,
982
]
]
] | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} (Compound) resembles {v} (Compound)",
"Atorvastatin"
],
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
]
] | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Conivaptan may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Conivaptan may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Conivaptan (Compound) resembles Atorvastatin (Compound) and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Conivaptan may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Conivaptan may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib |
DB00305 | DB10795 | 377 | 221 | [
"DDInter1232",
"DDInter1486"
] | Mitomycin | Poliovirus type 1 antigen (formaldehyde inactivated) | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries. | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. | Moderate | 1 | [
[
[
377,
24,
221
]
],
[
[
377,
64,
581
],
[
581,
24,
221
]
],
[
[
377,
63,
599
],
[
599,
24,
221
]
],
[
[
377,
24,
322
],
[
322,
24,
221
]
],
[
[
377,
25,
1510
],
[
1510,
24,
221
]
],
[
[
377,
25,
676
],
[
676,
63,
221
]
],
[
[
377,
24,
738
],
[
738,
63,
221
]
],
[
[
377,
64,
581
],
[
581,
25,
36
],
[
36,
24,
221
]
],
[
[
377,
63,
599
],
[
599,
24,
36
],
[
36,
24,
221
]
],
[
[
377,
24,
322
],
[
322,
24,
36
],
[
36,
24,
221
]
]
] | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
]
] | Mitomycin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) |
DB00863 | DB11613 | 1,194 | 1,519 | [
"DDInter1568",
"DDInter1924"
] | Ranitidine | Velpatasvir | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818] | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients . Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune responses . Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as velpatasvir. Notably, velpatasvir has a significantly higher barrier to resistance than the first generation NS5A inhibitors, such as and , making it a highly potent and reliable alternative for treatment of chronic Hepatitis C . In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Velpatasvir as first line therapy in combination with sofosbuvir for all six genotypes of Hepatitis C . Velpatasvir is currently only available within a fixed dose combination product as Epclusa with , another direct acting antiviral. Goals of therapy for Epclusa include the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality and risk of requiring a liver transplant . Since June 2016, Velpatasvir has been available as a fixed dose combination product with , as the commercially available product Epclusa. Epclusa is the first combination HCV product indicated for the treatment of all genotypes of Hepatitis C with or without cirrhosis. It is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and a high barrier to resistance . Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626]. | Moderate | 1 | [
[
[
1194,
24,
1519
]
],
[
[
1194,
24,
594
],
[
594,
24,
1519
]
],
[
[
1194,
23,
1384
],
[
1384,
24,
1519
]
],
[
[
1194,
40,
1127
],
[
1127,
24,
1519
]
],
[
[
1194,
24,
1040
],
[
1040,
25,
1519
]
],
[
[
1194,
24,
594
],
[
594,
63,
1374
],
[
1374,
24,
1519
]
],
[
[
1194,
23,
1384
],
[
1384,
63,
594
],
[
594,
24,
1519
]
],
[
[
1194,
23,
1283
],
[
1283,
24,
594
],
[
594,
24,
1519
]
],
[
[
1194,
40,
1127
],
[
1127,
24,
594
],
[
594,
24,
1519
]
],
[
[
1194,
25,
1406
],
[
1406,
62,
1135
],
[
1135,
23,
1519
]
]
] | [
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} (Compound) resembles {v} (Compound)",
"Nizatidine"
],
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
],
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} (Compound) resembles {v} (Compound)",
"Nizatidine"
],
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Velpatasvir"
]
]
] | Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Ranitidine (Compound) resembles Nizatidine (Compound) and Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Velpatasvir
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Ranitidine (Compound) resembles Nizatidine (Compound) and Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Ranitidine may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Velpatasvir |
DB09065 | DB09389 | 760 | 517 | [
"DDInter424",
"DDInter1315"
] | Cobicistat | Norgestrel | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
760,
24,
517
]
],
[
[
760,
63,
14
],
[
14,
23,
517
]
],
[
[
760,
25,
159
],
[
159,
63,
517
]
],
[
[
760,
63,
86
],
[
86,
24,
517
]
],
[
[
760,
64,
129
],
[
129,
24,
517
]
],
[
[
760,
25,
1362
],
[
1362,
24,
517
]
],
[
[
760,
24,
1619
],
[
1619,
63,
517
]
],
[
[
760,
25,
927
],
[
927,
64,
517
]
],
[
[
760,
63,
1040
],
[
1040,
25,
517
]
],
[
[
760,
62,
1101
],
[
1101,
25,
517
]
]
] | [
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norgestrel"
]
]
] | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Cobicistat may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Cobicistat may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Cobicistat may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Cobicistat may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Norgestrel
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may lead to a major life threatening interaction when taken with Norgestrel
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Norgestrel |
DB12267 | DB14443 | 1,476 | 987 | [
"DDInter233",
"DDInter1931"
] | Brigatinib | Vibrio cholerae CVD 103-HgR strain live antigen | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks. Cholera outbreaks remain a major global public health problem that mainly affects countries with limited access to clean water, poor hygiene, and proper sanitation; thus, effective vaccines to protect individuals against cholera disease are critical. The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera prevention to become available in the U.S. Vaxchora was later approved by the European Commission in April 2020. It is indicated for individuals aged two years and older. | Moderate | 1 | [
[
[
1476,
24,
987
]
],
[
[
1476,
63,
1468
],
[
1468,
24,
987
]
],
[
[
1476,
64,
1220
],
[
1220,
24,
987
]
],
[
[
1476,
24,
1619
],
[
1619,
24,
987
]
],
[
[
1476,
62,
168
],
[
168,
24,
987
]
],
[
[
1476,
25,
676
],
[
676,
63,
987
]
],
[
[
1476,
63,
1468
],
[
1468,
24,
1480
],
[
1480,
24,
987
]
],
[
[
1476,
64,
1220
],
[
1220,
24,
1468
],
[
1468,
24,
987
]
],
[
[
1476,
64,
351
],
[
351,
63,
1468
],
[
1468,
24,
987
]
],
[
[
1476,
24,
1619
],
[
1619,
63,
1468
],
[
1468,
24,
987
]
]
] | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
]
] | Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen |
DB00317 | DB04868 | 883 | 478 | [
"DDInter810",
"DDInter1293"
] | Gefitinib | Nilotinib | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
883,
24,
478
]
],
[
[
883,
6,
6017
],
[
6017,
45,
478
]
],
[
[
883,
7,
2703
],
[
2703,
46,
478
]
],
[
[
883,
18,
2183
],
[
2183,
57,
478
]
],
[
[
883,
6,
4055
],
[
4055,
57,
478
]
],
[
[
883,
21,
28766
],
[
28766,
60,
478
]
],
[
[
883,
23,
307
],
[
307,
23,
478
]
],
[
[
883,
24,
1040
],
[
1040,
63,
478
]
],
[
[
883,
24,
1559
],
[
1559,
24,
478
]
],
[
[
883,
63,
912
],
[
912,
24,
478
]
]
] | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} (Compound) upregulates {v} (Gene)",
"IKZF1"
],
[
"IKZF1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CHEK2"
],
[
"CHEK2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] | Gefitinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Gefitinib (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Nilotinib (Compound)
Gefitinib (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Gefitinib (Compound) binds CHEK2 (Gene) and CHEK2 (Gene) is downregulated by Nilotinib (Compound)
Gefitinib (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Nilotinib (Compound)
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB00749 | DB06605 | 59 | 1,409 | [
"DDInter699",
"DDInter108"
] | Etodolac | Apixaban | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Major | 2 | [
[
[
59,
25,
1409
]
],
[
[
59,
6,
6017
],
[
6017,
45,
1409
]
],
[
[
59,
21,
29666
],
[
29666,
60,
1409
]
],
[
[
59,
63,
1560
],
[
1560,
24,
1409
]
],
[
[
59,
24,
1220
],
[
1220,
24,
1409
]
],
[
[
59,
24,
384
],
[
384,
63,
1409
]
],
[
[
59,
25,
235
],
[
235,
64,
1409
]
],
[
[
59,
24,
1047
],
[
1047,
25,
1409
]
],
[
[
59,
63,
1061
],
[
1061,
25,
1409
]
],
[
[
59,
25,
39
],
[
39,
25,
1409
]
]
] | [
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} (Compound) causes {v} (Side Effect)",
"Melaena"
],
[
"Melaena",
"{u} (Side Effect) is caused by {v} (Compound)",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
]
] | Etodolac (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Apixaban (Compound)
Etodolac (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Apixaban (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Etodolac may lead to a major life threatening interaction when taken with Desirudin and Desirudin may lead to a major life threatening interaction when taken with Apixaban
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may lead to a major life threatening interaction when taken with Apixaban
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may lead to a major life threatening interaction when taken with Apixaban
Etodolac may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Apixaban |
DB00081 | DB10795 | 273 | 221 | [
"DDInter1838",
"DDInter1486"
] | Tositumomab | Poliovirus type 1 antigen (formaldehyde inactivated) | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells. | Moderate | 1 | [
[
[
273,
24,
221
]
],
[
[
273,
64,
581
],
[
581,
24,
221
]
],
[
[
273,
24,
599
],
[
599,
24,
221
]
],
[
[
273,
25,
1510
],
[
1510,
24,
221
]
],
[
[
273,
25,
676
],
[
676,
63,
221
]
],
[
[
273,
24,
738
],
[
738,
63,
221
]
],
[
[
273,
63,
1184
],
[
1184,
24,
221
]
],
[
[
273,
64,
581
],
[
581,
25,
36
],
[
36,
24,
221
]
],
[
[
273,
24,
599
],
[
599,
24,
36
],
[
36,
24,
221
]
],
[
[
273,
24,
384
],
[
384,
63,
36
],
[
36,
24,
221
]
]
] | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
]
] | Tositumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) |
DB01232 | DB08895 | 1,327 | 976 | [
"DDInter1640",
"DDInter1825"
] | Saquinavir | Tofacitinib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Major | 2 | [
[
[
1327,
25,
976
]
],
[
[
1327,
63,
660
],
[
660,
24,
976
]
],
[
[
1327,
25,
214
],
[
214,
63,
976
]
],
[
[
1327,
25,
868
],
[
868,
24,
976
]
],
[
[
1327,
64,
608
],
[
608,
24,
976
]
],
[
[
1327,
24,
98
],
[
98,
63,
976
]
],
[
[
1327,
25,
1011
],
[
1011,
25,
976
]
],
[
[
1327,
64,
1555
],
[
1555,
25,
976
]
],
[
[
1327,
63,
1101
],
[
1101,
25,
976
]
],
[
[
1327,
24,
1220
],
[
1220,
25,
976
]
]
] | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
]
] | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Saquinavir may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Saquinavir may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Saquinavir may lead to a major life threatening interaction when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Saquinavir may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib
Saquinavir may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may lead to a major life threatening interaction when taken with Tofacitinib
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Tofacitinib
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Tofacitinib |
DB00575 | DB01041 | 1,020 | 770 | [
"DDInter412",
"DDInter1789"
] | Clonidine | Thalidomide | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
1020,
24,
770
]
],
[
[
1020,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1020,
18,
2357
],
[
2357,
57,
770
]
],
[
[
1020,
21,
28789
],
[
28789,
60,
770
]
],
[
[
1020,
24,
849
],
[
849,
63,
770
]
],
[
[
1020,
1,
876
],
[
876,
24,
770
]
],
[
[
1020,
63,
1614
],
[
1614,
24,
770
]
],
[
[
1020,
24,
104
],
[
104,
24,
770
]
],
[
[
1020,
25,
1264
],
[
1264,
63,
770
]
],
[
[
1020,
1,
1084
],
[
1084,
63,
770
]
]
] | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} (Compound) downregulates {v} (Gene)",
"GRB7"
],
[
"GRB7",
"{u} (Gene) is downregulated by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} (Compound) resembles {v} (Compound)",
"Tizanidine"
],
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} (Compound) resembles {v} (Compound)",
"Lofexidine"
],
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
]
] | Clonidine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Clonidine (Compound) downregulates GRB7 (Gene) and GRB7 (Gene) is downregulated by Thalidomide (Compound)
Clonidine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Clonidine (Compound) resembles Tizanidine (Compound) and Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Clonidine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Clonidine (Compound) resembles Lofexidine (Compound) and Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide |
DB00656 | DB01169 | 827 | 57 | [
"DDInter1851",
"DDInter120"
] | Trazodone | Arsenic trioxide | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide. | Major | 2 | [
[
[
827,
25,
57
]
],
[
[
827,
6,
8374
],
[
8374,
45,
57
]
],
[
[
827,
23,
112
],
[
112,
23,
57
]
],
[
[
827,
24,
603
],
[
603,
63,
57
]
],
[
[
827,
24,
480
],
[
480,
24,
57
]
],
[
[
827,
63,
355
],
[
355,
24,
57
]
],
[
[
827,
40,
673
],
[
673,
63,
57
]
],
[
[
827,
40,
1630
],
[
1630,
25,
57
]
],
[
[
827,
24,
1616
],
[
1616,
64,
57
]
],
[
[
827,
25,
1154
],
[
1154,
64,
57
]
]
] | [
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
],
[
"Perphenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
]
] | Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Trazodone (Compound) resembles Aripiprazole (Compound) and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Trazodone (Compound) resembles Perphenazine (Compound) and Perphenazine may lead to a major life threatening interaction when taken with Arsenic trioxide
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may lead to a major life threatening interaction when taken with Arsenic trioxide
Trazodone may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Arsenic trioxide |
DB00722 | DB11921 | 743 | 1,019 | [
"DDInter1079",
"DDInter492"
] | Lisinopril | Deflazacort | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
743,
24,
1019
]
],
[
[
743,
24,
959
],
[
959,
24,
1019
]
],
[
[
743,
23,
286
],
[
286,
24,
1019
]
],
[
[
743,
63,
1512
],
[
1512,
24,
1019
]
],
[
[
743,
1,
1058
],
[
1058,
24,
1019
]
],
[
[
743,
35,
1144
],
[
1144,
24,
1019
]
],
[
[
743,
40,
1638
],
[
1638,
24,
1019
]
],
[
[
743,
24,
1220
],
[
1220,
25,
1019
]
],
[
[
743,
25,
1510
],
[
1510,
25,
1019
]
],
[
[
743,
24,
959
],
[
959,
63,
1072
],
[
1072,
23,
1019
]
]
] | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
],
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Deflazacort"
]
]
] | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lisinopril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lisinopril (Compound) resembles Nateglinide (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort
Lisinopril may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Deflazacort
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort |
DB00495 | DB00877 | 139 | 629 | [
"DDInter1961",
"DDInter1678"
] | Zidovudine | Sirolimus | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem] | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex. | Moderate | 1 | [
[
[
139,
24,
629
]
],
[
[
139,
6,
4973
],
[
4973,
45,
629
]
],
[
[
139,
6,
8155
],
[
8155,
46,
629
]
],
[
[
139,
7,
9681
],
[
9681,
57,
629
]
],
[
[
139,
21,
29203
],
[
29203,
60,
629
]
],
[
[
139,
24,
167
],
[
167,
24,
629
]
],
[
[
139,
23,
752
],
[
752,
24,
629
]
],
[
[
139,
63,
599
],
[
599,
24,
629
]
],
[
[
139,
24,
1017
],
[
1017,
63,
629
]
],
[
[
139,
1,
1477
],
[
1477,
63,
629
]
]
] | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"ABCC5"
],
[
"ABCC5",
"{u} (Gene) is upregulated by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} (Compound) upregulates {v} (Gene)",
"THAP11"
],
[
"THAP11",
"{u} (Gene) is downregulated by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} (Compound) causes {v} (Side Effect)",
"Aspartate aminotransferase increased"
],
[
"Aspartate aminotransferase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} (Compound) resembles {v} (Compound)",
"Telbivudine"
],
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
]
] | Zidovudine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Zidovudine (Compound) binds ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Sirolimus (Compound)
Zidovudine (Compound) upregulates THAP11 (Gene) and THAP11 (Gene) is downregulated by Sirolimus (Compound)
Zidovudine (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Zidovudine (Compound) resembles Telbivudine (Compound) and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus |
DB00975 | DB08886 | 1,317 | 637 | [
"DDInter573",
"DDInter126"
] | Dipyridamole | Asparaginase Erwinia chrysanthemi | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. | Moderate | 1 | [
[
[
1317,
24,
637
]
],
[
[
1317,
25,
936
],
[
936,
24,
637
]
],
[
[
1317,
63,
1274
],
[
1274,
24,
637
]
],
[
[
1317,
25,
1421
],
[
1421,
63,
637
]
],
[
[
1317,
64,
553
],
[
553,
24,
637
]
],
[
[
1317,
24,
848
],
[
848,
24,
637
]
],
[
[
1317,
24,
1496
],
[
1496,
63,
637
]
],
[
[
1317,
25,
936
],
[
936,
63,
1274
],
[
1274,
24,
637
]
],
[
[
1317,
63,
1274
],
[
1274,
24,
167
],
[
167,
24,
637
]
],
[
[
1317,
25,
1421
],
[
1421,
64,
392
],
[
392,
24,
637
]
]
] | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
],
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
],
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] | Dipyridamole may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi |
DB00771 | DB01114 | 262 | 272 | [
"DDInter397",
"DDInter362"
] | Clidinium | Chlorpheniramine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
262,
24,
272
]
],
[
[
262,
24,
358
],
[
358,
63,
272
]
],
[
[
262,
63,
128
],
[
128,
24,
272
]
],
[
[
262,
24,
314
],
[
314,
24,
272
]
],
[
[
262,
74,
576
],
[
576,
24,
272
]
],
[
[
262,
35,
1301
],
[
1301,
63,
272
]
],
[
[
262,
74,
675
],
[
675,
25,
272
]
],
[
[
262,
25,
306
],
[
306,
25,
272
]
],
[
[
262,
64,
1621
],
[
1621,
25,
272
]
],
[
[
262,
63,
508
],
[
508,
35,
272
]
]
] | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
],
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
]
] | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clidinium (Compound) resembles Methadone (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clidinium (Compound) resembles Levacetylmethadol (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Levacetylmethadol and Levacetylmethadol may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clidinium (Compound) resembles Dextropropoxyphene (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Chlorpheniramine
Clidinium may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may lead to a major life threatening interaction when taken with Chlorpheniramine
Clidinium may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Chlorpheniramine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Chlorpheniramine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine |
DB00717 | DB12332 | 1,197 | 1,619 | [
"DDInter1312",
"DDInter1626"
] | Norethisterone | Rucaparib | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [norethynodrel] and [lynestrenol]. Norethisterone mimics the actions of endogenous [progesterone], albeit with a greater potency, and is used on its own or in combination with estrogen derivatives in a variety of applications including contraception and hormone replacement therapy.[L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an oral contraceptive until 1962. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1197,
24,
1619
]
],
[
[
1197,
24,
259
],
[
259,
24,
1619
]
],
[
[
1197,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
1197,
24,
1501
],
[
1501,
63,
1619
]
],
[
[
1197,
23,
14
],
[
14,
24,
1619
]
],
[
[
1197,
64,
1101
],
[
1101,
24,
1619
]
],
[
[
1197,
1,
1561
],
[
1561,
24,
1619
]
],
[
[
1197,
25,
1476
],
[
1476,
24,
1619
]
],
[
[
1197,
40,
989
],
[
989,
24,
1619
]
],
[
[
1197,
24,
478
],
[
478,
25,
1619
]
]
] | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
],
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Progesterone"
],
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
]
] | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Rucaparib |
DB11581 | DB14443 | 1,456 | 987 | [
"DDInter1926",
"DDInter1931"
] | Venetoclax | Vibrio cholerae CVD 103-HgR strain live antigen | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks. Cholera outbreaks remain a major global public health problem that mainly affects countries with limited access to clean water, poor hygiene, and proper sanitation; thus, effective vaccines to protect individuals against cholera disease are critical. The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera prevention to become available in the U.S. Vaxchora was later approved by the European Commission in April 2020. It is indicated for individuals aged two years and older. | Moderate | 1 | [
[
[
1456,
24,
987
]
],
[
[
1456,
64,
1468
],
[
1468,
24,
987
]
],
[
[
1456,
25,
351
],
[
351,
24,
987
]
],
[
[
1456,
24,
1583
],
[
1583,
24,
987
]
],
[
[
1456,
63,
259
],
[
259,
24,
987
]
],
[
[
1456,
25,
676
],
[
676,
63,
987
]
],
[
[
1456,
64,
1468
],
[
1468,
24,
1480
],
[
1480,
24,
987
]
],
[
[
1456,
25,
351
],
[
351,
63,
1468
],
[
1468,
24,
987
]
],
[
[
1456,
24,
1583
],
[
1583,
63,
305
],
[
305,
24,
987
]
],
[
[
1456,
63,
259
],
[
259,
24,
1480
],
[
1480,
24,
987
]
]
] | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
]
] | Venetoclax may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen |
DB00460 | DB12364 | 612 | 1,421 | [
"DDInter1929",
"DDInter200"
] | Verteporfin | Betrixaban | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients . | Moderate | 1 | [
[
[
612,
24,
1421
]
],
[
[
612,
24,
714
],
[
714,
25,
1421
]
],
[
[
612,
63,
291
],
[
291,
25,
1421
]
],
[
[
612,
24,
714
],
[
714,
23,
944
],
[
944,
62,
1421
]
],
[
[
612,
24,
1347
],
[
1347,
23,
297
],
[
297,
23,
1421
]
],
[
[
612,
24,
392
],
[
392,
64,
1091
],
[
1091,
24,
1421
]
],
[
[
612,
63,
291
],
[
291,
23,
297
],
[
297,
23,
1421
]
],
[
[
612,
24,
868
],
[
868,
63,
1091
],
[
1091,
24,
1421
]
],
[
[
612,
63,
1061
],
[
1061,
23,
944
],
[
944,
62,
1421
]
],
[
[
612,
21,
29750
],
[
29750,
60,
500
],
[
500,
25,
1421
]
]
] | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} (Compound) causes {v} (Side Effect)",
"Injection site pain"
],
[
"Injection site pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
]
] | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may lead to a major life threatening interaction when taken with Betrixaban
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Verteporfin (Compound) causes Injection site pain (Side Effect) and Injection site pain (Side Effect) is caused by Enoxaparin (Compound) and Enoxaparin may lead to a major life threatening interaction when taken with Betrixaban |
DB00283 | DB01452 | 701 | 993 | [
"DDInter395",
"DDInter532"
] | Clemastine | Diamorphine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs. As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom. | Moderate | 1 | [
[
[
701,
24,
993
]
],
[
[
701,
24,
421
],
[
421,
40,
993
]
],
[
[
701,
24,
475
],
[
475,
25,
993
]
],
[
[
701,
24,
13
],
[
13,
24,
993
]
],
[
[
701,
35,
1594
],
[
1594,
24,
993
]
],
[
[
701,
24,
849
],
[
849,
63,
993
]
],
[
[
701,
24,
421
],
[
421,
1,
1044
],
[
1044,
40,
993
]
],
[
[
701,
24,
475
],
[
475,
40,
1044
],
[
1044,
40,
993
]
],
[
[
701,
24,
13
],
[
13,
63,
421
],
[
421,
40,
993
]
],
[
[
701,
35,
1594
],
[
1594,
63,
421
],
[
421,
40,
993
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Codeine"
],
[
"Codeine",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} (Compound) resembles {v} (Compound)",
"Codeine"
],
[
"Codeine",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
]
]
] | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Diamorphine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Diamorphine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Codeine (Compound) and Codeine (Compound) resembles Diamorphine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine (Compound) resembles Codeine (Compound) and Codeine (Compound) resembles Diamorphine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound) |
DB01229 | DB11952 | 973 | 800 | [
"DDInter1378",
"DDInter612"
] | Paclitaxel (protein-bound) | Duvelisib | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018. | Moderate | 1 | [
[
[
973,
24,
800
]
],
[
[
973,
24,
310
],
[
310,
24,
800
]
],
[
[
973,
63,
467
],
[
467,
24,
800
]
],
[
[
973,
24,
1476
],
[
1476,
63,
800
]
],
[
[
973,
63,
609
],
[
609,
25,
800
]
],
[
[
973,
24,
760
],
[
760,
25,
800
]
],
[
[
973,
25,
1292
],
[
1292,
25,
800
]
],
[
[
973,
64,
1057
],
[
1057,
25,
800
]
],
[
[
973,
25,
676
],
[
676,
64,
800
]
],
[
[
973,
24,
310
],
[
310,
63,
467
],
[
467,
24,
800
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Duvelisib
Paclitaxel may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Duvelisib
Paclitaxel may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Duvelisib
Paclitaxel may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Duvelisib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib |
DB00450 | DB00687 | 78 | 870 | [
"DDInter603",
"DDInter747"
] | Droperidol | Fludrocortisone | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Major | 2 | [
[
[
78,
25,
870
]
],
[
[
78,
25,
167
],
[
167,
40,
870
]
],
[
[
78,
21,
28835
],
[
28835,
60,
870
]
],
[
[
78,
24,
688
],
[
688,
62,
870
]
],
[
[
78,
25,
1674
],
[
1674,
62,
870
]
],
[
[
78,
24,
28
],
[
28,
63,
870
]
],
[
[
78,
25,
392
],
[
392,
63,
870
]
],
[
[
78,
1,
1300
],
[
1300,
24,
870
]
],
[
[
78,
24,
355
],
[
355,
24,
870
]
],
[
[
78,
25,
1287
],
[
1287,
24,
870
]
]
] | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperglycaemia"
],
[
"Hyperglycaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} (Compound) resembles {v} (Compound)",
"Haloperidol"
],
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
]
] | Droperidol may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Fludrocortisone (Compound)
Droperidol (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Fludrocortisone (Compound)
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone
Droperidol may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Droperidol may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Droperidol (Compound) resembles Haloperidol (Compound) and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone
Droperidol may lead to a major life threatening interaction when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone |
DB01041 | DB11632 | 770 | 580 | [
"DDInter1789",
"DDInter1343"
] | Thalidomide | Opicapone | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management of these symptoms through the use of a dopamine agonist, a monoamine oxidase B inhibitor (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using a modified-release formulation of levodopa. Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. Opicapone was approved for use by the European Commission in June 2016 and the FDA in April 2020. It is marketed under the brand name Ongentys as once-daily oral capsules. Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase inhibitors. | Moderate | 1 | [
[
[
770,
24,
580
]
],
[
[
770,
63,
104
],
[
104,
24,
580
]
],
[
[
770,
24,
830
],
[
830,
24,
580
]
],
[
[
770,
25,
1053
],
[
1053,
25,
580
]
],
[
[
770,
63,
104
],
[
104,
1,
830
],
[
830,
24,
580
]
],
[
[
770,
24,
830
],
[
830,
40,
104
],
[
104,
24,
580
]
],
[
[
770,
24,
649
],
[
649,
63,
401
],
[
401,
24,
580
]
],
[
[
770,
63,
1219
],
[
1219,
40,
830
],
[
830,
24,
580
]
],
[
[
770,
63,
999
],
[
999,
24,
401
],
[
401,
24,
580
]
],
[
[
770,
24,
222
],
[
222,
24,
649
],
[
649,
24,
580
]
]
] | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
]
] | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thalidomide may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opicapone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Opicapone |
DB00518 | DB12500 | 510 | 283 | [
"DDInter35",
"DDInter714"
] | Albendazole | Fedratinib | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
510,
24,
283
]
],
[
[
510,
24,
351
],
[
351,
23,
283
]
],
[
[
510,
24,
327
],
[
327,
24,
283
]
],
[
[
510,
63,
529
],
[
529,
24,
283
]
],
[
[
510,
23,
978
],
[
978,
24,
283
]
],
[
[
510,
24,
1654
],
[
1654,
63,
283
]
],
[
[
510,
62,
752
],
[
752,
24,
283
]
],
[
[
510,
24,
1236
],
[
1236,
25,
283
]
],
[
[
510,
23,
307
],
[
307,
25,
283
]
],
[
[
510,
63,
798
],
[
798,
25,
283
]
]
] | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
],
[
"Abametapir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Praziquantel"
],
[
"Praziquantel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abametapir may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Albendazole may cause a minor interaction that can limit clinical effects when taken with Praziquantel and Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Albendazole may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may lead to a major life threatening interaction when taken with Fedratinib
Albendazole may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may lead to a major life threatening interaction when taken with Fedratinib
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may lead to a major life threatening interaction when taken with Fedratinib |
DB00555 | DB01142 | 706 | 1,264 | [
"DDInter1020",
"DDInter593"
] | Lamotrigine | Doxepin | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. Lamotrigine has relatively few side-effects and does not require laboratory monitoring. While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850] | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics. | Moderate | 1 | [
[
[
706,
24,
1264
]
],
[
[
706,
24,
401
],
[
401,
24,
1264
]
],
[
[
706,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
706,
24,
649
],
[
649,
63,
1264
]
],
[
[
706,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
706,
21,
29226
],
[
29226,
60,
1264
]
],
[
[
706,
40,
1275
],
[
1275,
24,
1264
]
],
[
[
706,
24,
1487
],
[
1487,
64,
1264
]
],
[
[
706,
24,
1376
],
[
1376,
35,
1264
]
],
[
[
706,
24,
820
],
[
820,
74,
1264
]
]
] | [
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} (Compound) causes {v} (Side Effect)",
"Sinusitis"
],
[
"Sinusitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} (Compound) resembles {v} (Compound)",
"Triamterene"
],
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
]
] | Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Lamotrigine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Lamotrigine (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Doxepin (Compound)
Lamotrigine (Compound) resembles Triamterene (Compound) and Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Doxepin
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Doxepin (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin |
DB00794 | DB05679 | 759 | 1,683 | [
"DDInter1521",
"DDInter1907"
] | Primidone | Ustekinumab | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada. | Moderate | 1 | [
[
[
759,
24,
1683
]
],
[
[
759,
24,
1042
],
[
1042,
24,
1683
]
],
[
[
759,
25,
1362
],
[
1362,
63,
1683
]
],
[
[
759,
24,
1093
],
[
1093,
63,
1683
]
],
[
[
759,
63,
1573
],
[
1573,
24,
1683
]
],
[
[
759,
25,
478
],
[
478,
24,
1683
]
],
[
[
759,
64,
613
],
[
613,
24,
1683
]
],
[
[
759,
62,
608
],
[
608,
24,
1683
]
],
[
[
759,
40,
157
],
[
157,
24,
1683
]
],
[
[
759,
1,
697
],
[
697,
24,
1683
]
]
] | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Ethotoin"
],
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
]
] | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone may lead to a major life threatening interaction when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone (Compound) resembles Ethotoin (Compound) and Ethotoin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab |
DB00396 | DB09098 | 989 | 98 | [
"DDInter1530",
"DDInter1700"
] | Progesterone (topical) | Somatrem | Progesterone can cause cancer according to an independent committee of scientific and health experts. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
989,
24,
98
]
],
[
[
989,
1,
284
],
[
284,
24,
98
]
],
[
[
989,
24,
159
],
[
159,
63,
98
]
],
[
[
989,
24,
609
],
[
609,
24,
98
]
],
[
[
989,
63,
1647
],
[
1647,
24,
98
]
],
[
[
989,
40,
870
],
[
870,
24,
98
]
],
[
[
989,
25,
1456
],
[
1456,
63,
98
]
],
[
[
989,
63,
1101
],
[
1101,
25,
98
]
],
[
[
989,
1,
284
],
[
284,
24,
159
],
[
159,
63,
98
]
],
[
[
989,
24,
159
],
[
159,
63,
608
],
[
608,
23,
98
]
]
] | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Finasteride"
],
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Finasteride"
],
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
]
] | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone (Compound) resembles Finasteride (Compound) and Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Progesterone (Compound) resembles Finasteride (Compound) and Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem |
DB00938 | DB06706 | 455 | 468 | [
"DDInter1635",
"DDInter985"
] | Salmeterol | Isometheptene | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994. | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
455,
24,
468
]
],
[
[
455,
18,
3023
],
[
3023,
57,
468
]
],
[
[
455,
24,
480
],
[
480,
24,
468
]
],
[
[
455,
63,
1100
],
[
1100,
24,
468
]
],
[
[
455,
24,
144
],
[
144,
63,
468
]
],
[
[
455,
24,
1629
],
[
1629,
64,
468
]
],
[
[
455,
24,
1053
],
[
1053,
25,
468
]
],
[
[
455,
63,
551
],
[
551,
25,
468
]
],
[
[
455,
18,
3023
],
[
3023,
17,
3553
],
[
3553,
46,
468
]
],
[
[
455,
24,
480
],
[
480,
24,
1354
],
[
1354,
24,
468
]
]
] | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} (Compound) downregulates {v} (Gene)",
"RUVBL1"
],
[
"RUVBL1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} (Compound) downregulates {v} (Gene)",
"RUVBL1"
],
[
"RUVBL1",
"{u} (Gene) regulates {v} (Gene)",
"CRIP1"
],
[
"CRIP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droxidopa"
],
[
"Droxidopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
]
] | Salmeterol (Compound) downregulates RUVBL1 (Gene) and RUVBL1 (Gene) is downregulated by Isometheptene (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Isometheptene
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Isometheptene
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may lead to a major life threatening interaction when taken with Isometheptene
Salmeterol (Compound) downregulates RUVBL1 (Gene) and RUVBL1 (Gene) regulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Isometheptene (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene |
DB08899 | DB09098 | 129 | 98 | [
"DDInter649",
"DDInter1700"
] | Enzalutamide | Somatrem | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
129,
24,
98
]
],
[
[
129,
25,
1612
],
[
1612,
62,
98
]
],
[
[
129,
62,
608
],
[
608,
23,
98
]
],
[
[
129,
64,
168
],
[
168,
23,
98
]
],
[
[
129,
23,
1459
],
[
1459,
23,
98
]
],
[
[
129,
63,
671
],
[
671,
24,
98
]
],
[
[
129,
64,
336
],
[
336,
24,
98
]
],
[
[
129,
25,
159
],
[
159,
63,
98
]
],
[
[
129,
24,
1450
],
[
1450,
24,
98
]
],
[
[
129,
25,
996
],
[
996,
24,
98
]
]
] | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
],
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
]
] | Enzalutamide may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Enzalutamide may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Enzalutamide may lead to a major life threatening interaction when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Enzalutamide may lead to a major life threatening interaction when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Somatrem |
DB01396 | DB09472 | 1,482 | 1,383 | [
"DDInter553",
"DDInter1693"
] | Digitoxin | Sodium sulfate | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions. | Minor | 0 | [
[
[
1482,
23,
1383
]
],
[
[
1482,
40,
1252
],
[
1252,
23,
1383
]
],
[
[
1482,
63,
609
],
[
609,
24,
1383
]
],
[
[
1482,
24,
1154
],
[
1154,
24,
1383
]
],
[
[
1482,
64,
1166
],
[
1166,
25,
1383
]
],
[
[
1482,
40,
1252
],
[
1252,
25,
609
],
[
609,
24,
1383
]
],
[
[
1482,
63,
609
],
[
609,
64,
1252
],
[
1252,
23,
1383
]
],
[
[
1482,
63,
1466
],
[
1466,
63,
1252
],
[
1252,
23,
1383
]
],
[
[
1482,
24,
1154
],
[
1154,
63,
1252
],
[
1252,
23,
1383
]
],
[
[
1482,
1,
11781
],
[
11781,
40,
1252
],
[
1252,
23,
1383
]
]
] | [
[
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Deslanoside"
],
[
"Deslanoside",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
]
] | Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Digitoxin may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Sodium sulfate
Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Digitoxin (Compound) resembles Deslanoside (Compound) and Deslanoside (Compound) resembles Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate |
DB00477 | DB01087 | 216 | 1,520 | [
"DDInter363",
"DDInter1520"
] | Chlorpromazine | Primaquine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404) | Moderate | 1 | [
[
[
216,
24,
1520
]
],
[
[
216,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
216,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
216,
21,
28852
],
[
28852,
60,
1520
]
],
[
[
216,
23,
112
],
[
112,
23,
1520
]
],
[
[
216,
1,
508
],
[
508,
24,
1520
]
],
[
[
216,
63,
618
],
[
618,
24,
1520
]
],
[
[
216,
24,
1342
],
[
1342,
63,
1520
]
],
[
[
216,
24,
1133
],
[
1133,
24,
1520
]
],
[
[
216,
1,
1237
],
[
1237,
63,
1520
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) causes {v} (Side Effect)",
"Leukopenia"
],
[
"Leukopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
],
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
]
] | Chlorpromazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Chlorpromazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Chlorpromazine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Primaquine (Compound)
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Primaquine
Chlorpromazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Primaquine
Chlorpromazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine |
DB04868 | DB06772 | 478 | 310 | [
"DDInter1293",
"DDInter259"
] | Nilotinib | Cabazitaxel | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Moderate | 1 | [
[
[
478,
24,
310
]
],
[
[
478,
63,
973
],
[
973,
24,
310
]
],
[
[
478,
6,
4973
],
[
4973,
45,
310
]
],
[
[
478,
21,
28894
],
[
28894,
60,
310
]
],
[
[
478,
62,
307
],
[
307,
23,
310
]
],
[
[
478,
24,
800
],
[
800,
63,
310
]
],
[
[
478,
25,
868
],
[
868,
63,
310
]
],
[
[
478,
74,
1419
],
[
1419,
24,
310
]
],
[
[
478,
64,
798
],
[
798,
24,
310
]
],
[
[
478,
24,
1430
],
[
1430,
24,
310
]
]
] | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac failure"
],
[
"Cardiac failure",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
]
] | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Nilotinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cabazitaxel (Compound)
Nilotinib (Compound) causes Cardiac failure (Side Effect) and Cardiac failure (Side Effect) is caused by Cabazitaxel (Compound)
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Cabazitaxel
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Nilotinib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Nilotinib (Compound) resembles Imatinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Nilotinib may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel |
DB08816 | DB08893 | 578 | 271 | [
"DDInter1802",
"DDInter1229"
] | Ticagrelor | Mirabegron | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity, which is responsible both for the therapeutic effects of these medications and their broad range of adverse effects. Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use alongside solifenacin in refractory cases. Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder. An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity. Mirabegron is also used in other jurisdictions across the globe, including Canada, the EU, and Japan. | Minor | 0 | [
[
[
578,
23,
271
]
],
[
[
578,
62,
1523
],
[
1523,
40,
271
]
],
[
[
578,
6,
4973
],
[
4973,
45,
271
]
],
[
[
578,
21,
28722
],
[
28722,
60,
271
]
],
[
[
578,
25,
129
],
[
129,
62,
271
]
],
[
[
578,
63,
1220
],
[
1220,
23,
271
]
],
[
[
578,
24,
351
],
[
351,
62,
271
]
],
[
[
578,
24,
868
],
[
868,
23,
271
]
],
[
[
578,
64,
609
],
[
609,
23,
271
]
],
[
[
578,
63,
121
],
[
121,
24,
271
]
]
] | [
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Labetalol"
],
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
]
]
] | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Labetalol and Labetalol (Compound) resembles Mirabegron (Compound)
Ticagrelor (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound)
Ticagrelor (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Mirabegron (Compound)
Ticagrelor may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ticagrelor may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron |
DB00701 | DB08882 | 1,091 | 1,281 | [
"DDInter90",
"DDInter1070"
] | Amprenavir | Linagliptin | Amprenavir is a protease inhibitor used to treat HIV infection. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011. | Moderate | 1 | [
[
[
1091,
24,
1281
]
],
[
[
1091,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1091,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
1091,
21,
29081
],
[
29081,
60,
1281
]
],
[
[
1091,
63,
251
],
[
251,
24,
1281
]
],
[
[
1091,
24,
1320
],
[
1320,
63,
1281
]
],
[
[
1091,
24,
868
],
[
868,
24,
1281
]
],
[
[
1091,
25,
629
],
[
629,
24,
1281
]
],
[
[
1091,
25,
1019
],
[
1019,
63,
1281
]
],
[
[
1091,
23,
609
],
[
609,
24,
1281
]
]
] | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
"Alogliptin",
"{u} (Compound) resembles {v} (Compound)",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} (Compound) causes {v} (Side Effect)",
"Angioedema"
],
[
"Angioedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
]
] | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Amprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Amprenavir (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Linagliptin (Compound)
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Amprenavir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Amprenavir may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin |
DB00808 | DB01124 | 1,605 | 1,411 | [
"DDInter916",
"DDInter1828"
] | Indapamide | Tolbutamide | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
1605,
24,
1411
]
],
[
[
1605,
24,
959
],
[
959,
40,
1411
]
],
[
[
1605,
63,
245
],
[
245,
40,
1411
]
],
[
[
1605,
21,
28746
],
[
28746,
60,
1411
]
],
[
[
1605,
63,
660
],
[
660,
23,
1411
]
],
[
[
1605,
24,
1296
],
[
1296,
63,
1411
]
],
[
[
1605,
62,
126
],
[
126,
24,
1411
]
],
[
[
1605,
63,
1274
],
[
1274,
24,
1411
]
],
[
[
1605,
24,
480
],
[
480,
24,
1411
]
],
[
[
1605,
1,
1335
],
[
1335,
24,
1411
]
]
] | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
]
] | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Indapamide (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Tolbutamide (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Indapamide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Indapamide (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB00443 | DB15093 | 251 | 1,654 | [
"DDInter195",
"DDInter1698"
] | Betamethasone | Somapacitan | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
251,
24,
1654
]
],
[
[
251,
24,
433
],
[
433,
24,
1654
]
],
[
[
251,
63,
176
],
[
176,
24,
1654
]
],
[
[
251,
40,
167
],
[
167,
24,
1654
]
],
[
[
251,
25,
676
],
[
676,
24,
1654
]
],
[
[
251,
1,
1573
],
[
1573,
24,
1654
]
],
[
[
251,
23,
455
],
[
455,
24,
1654
]
],
[
[
251,
63,
1101
],
[
1101,
25,
1654
]
],
[
[
251,
24,
433
],
[
433,
63,
168
],
[
168,
23,
1654
]
],
[
[
251,
63,
176
],
[
176,
24,
168
],
[
168,
23,
1654
]
]
] | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somapacitan"
]
]
] | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Betamethasone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Betamethasone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somapacitan
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan |
DB00782 | DB01173 | 1,123 | 358 | [
"DDInter1535",
"DDInter1349"
] | Propantheline | Orphenadrine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1123,
24,
358
]
],
[
[
1123,
24,
211
],
[
211,
1,
358
]
],
[
[
1123,
24,
272
],
[
272,
24,
358
]
],
[
[
1123,
24,
820
],
[
820,
63,
358
]
],
[
[
1123,
63,
1164
],
[
1164,
1,
358
]
],
[
[
1123,
24,
1405
],
[
1405,
40,
358
]
],
[
[
1123,
63,
675
],
[
675,
40,
358
]
],
[
[
1123,
63,
128
],
[
128,
24,
358
]
],
[
[
1123,
6,
4304
],
[
4304,
45,
358
]
],
[
[
1123,
21,
29232
],
[
29232,
60,
358
]
]
] | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Orphenadrine"
]
]
] | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Orphenadrine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Orphenadrine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Orphenadrine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Propantheline (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Orphenadrine (Compound)
Propantheline (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Orphenadrine (Compound) |
DB06688 | DB09570 | 1,430 | 1,480 | [
"DDInter1677",
"DDInter1002"
] | Sipuleucel-T | Ixazomib | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $ | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Moderate | 1 | [
[
[
1430,
24,
1480
]
],
[
[
1430,
63,
268
],
[
268,
24,
1480
]
],
[
[
1430,
24,
310
],
[
310,
24,
1480
]
],
[
[
1430,
24,
110
],
[
110,
63,
1480
]
],
[
[
1430,
24,
375
],
[
375,
25,
1480
]
],
[
[
1430,
24,
676
],
[
676,
64,
1480
]
],
[
[
1430,
63,
1377
],
[
1377,
25,
1480
]
],
[
[
1430,
64,
1064
],
[
1064,
25,
1480
]
],
[
[
1430,
63,
268
],
[
268,
24,
440
],
[
440,
24,
1480
]
],
[
[
1430,
63,
453
],
[
453,
63,
268
],
[
268,
24,
1480
]
]
] | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
],
[
"Polatuzumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
],
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
],
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
]
] | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Ixazomib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ixazomib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Ixazomib
Sipuleucel-T may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Ixazomib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Linezolid and Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib |
DB08893 | DB12130 | 271 | 1,017 | [
"DDInter1229",
"DDInter1094"
] | Mirabegron | Lorlatinib | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significant antimuscarinic activity, which is responsible both for the therapeutic effects of these medications and their broad range of adverse effects. Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its use alongside solifenacin in refractory cases. Mirabegron first received FDA approval in 2012, under the brand name Myrbetriq, for the treatment of adults with overactive bladder. An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Minor | 0 | [
[
[
271,
23,
1017
]
],
[
[
271,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
271,
62,
126
],
[
126,
24,
1017
]
],
[
[
271,
64,
888
],
[
888,
24,
1017
]
],
[
[
271,
63,
187
],
[
187,
24,
1017
]
],
[
[
271,
23,
951
],
[
951,
24,
1017
]
],
[
[
271,
24,
214
],
[
214,
24,
1017
]
],
[
[
271,
23,
159
],
[
159,
63,
1017
]
],
[
[
271,
25,
1670
],
[
1670,
24,
1017
]
],
[
[
271,
25,
1456
],
[
1456,
25,
1017
]
]
] | [
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
],
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
]
] | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirabegron may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirabegron may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone and Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirabegron may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirabegron may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Mirabegron may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib |
DB00518 | DB04855 | 510 | 540 | [
"DDInter35",
"DDInter602"
] | Albendazole | Dronedarone | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone. | Moderate | 1 | [
[
[
510,
24,
540
]
],
[
[
510,
6,
8374
],
[
8374,
45,
540
]
],
[
[
510,
21,
28883
],
[
28883,
60,
540
]
],
[
[
510,
62,
608
],
[
608,
24,
540
]
],
[
[
510,
23,
1220
],
[
1220,
24,
540
]
],
[
[
510,
24,
214
],
[
214,
63,
540
]
],
[
[
510,
24,
629
],
[
629,
24,
540
]
],
[
[
510,
63,
1101
],
[
1101,
24,
540
]
],
[
[
510,
24,
129
],
[
129,
64,
540
]
],
[
[
510,
24,
392
],
[
392,
25,
540
]
]
] | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
]
] | Albendazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Albendazole (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dronedarone (Compound)
Albendazole may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Albendazole may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Dronedarone
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Dronedarone |
DB00264 | DB09333 | 88 | 278 | [
"DDInter1200",
"DDInter963"
] | Metoprolol | Iopodic acid | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978. | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada. On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status. | Moderate | 1 | [
[
[
88,
24,
278
]
],
[
[
88,
63,
1648
],
[
1648,
24,
278
]
],
[
[
88,
24,
1527
],
[
1527,
24,
278
]
],
[
[
88,
40,
726
],
[
726,
24,
278
]
],
[
[
88,
1,
819
],
[
819,
24,
278
]
],
[
[
88,
63,
1648
],
[
1648,
24,
461
],
[
461,
24,
278
]
],
[
[
88,
24,
1527
],
[
1527,
63,
461
],
[
461,
24,
278
]
],
[
[
88,
40,
726
],
[
726,
24,
1527
],
[
1527,
24,
278
]
],
[
[
88,
40,
887
],
[
887,
63,
1648
],
[
1648,
24,
278
]
],
[
[
88,
1,
819
],
[
819,
63,
1648
],
[
1648,
24,
278
]
]
] | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Betaxolol"
],
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Betaxolol"
],
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
]
] | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol (Compound) resembles Betaxolol (Compound) and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol (Compound) resembles Betaxolol (Compound) and Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid |
DB00549 | DB08903 | 522 | 996 | [
"DDInter1955",
"DDInter170"
] | Zafirlukast | Bedaquiline | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Moderate | 1 | [
[
[
522,
24,
996
]
],
[
[
522,
6,
8374
],
[
8374,
45,
996
]
],
[
[
522,
21,
29106
],
[
29106,
60,
996
]
],
[
[
522,
24,
112
],
[
112,
23,
996
]
],
[
[
522,
24,
350
],
[
350,
24,
996
]
],
[
[
522,
24,
1613
],
[
1613,
63,
996
]
],
[
[
522,
63,
491
],
[
491,
24,
996
]
],
[
[
522,
25,
1377
],
[
1377,
25,
996
]
],
[
[
522,
24,
124
],
[
124,
64,
996
]
],
[
[
522,
63,
322
],
[
322,
25,
996
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Myalgia"
],
[
"Myalgia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
]
] | Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Zafirlukast (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Bedaquiline (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Zafirlukast may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Bedaquiline
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Bedaquiline
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Bedaquiline |
DB06335 | DB11652 | 761 | 1,155 | [
"DDInter1646",
"DDInter1891"
] | Saxagliptin | Tucatinib | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Moderate | 1 | [
[
[
761,
24,
1155
]
],
[
[
761,
63,
222
],
[
222,
23,
1155
]
],
[
[
761,
64,
1101
],
[
1101,
23,
1155
]
],
[
[
761,
24,
659
],
[
659,
24,
1155
]
],
[
[
761,
63,
609
],
[
609,
24,
1155
]
],
[
[
761,
24,
1320
],
[
1320,
63,
1155
]
],
[
[
761,
24,
351
],
[
351,
64,
1155
]
],
[
[
761,
24,
1618
],
[
1618,
25,
1155
]
],
[
[
761,
63,
455
],
[
455,
25,
1155
]
],
[
[
761,
63,
222
],
[
222,
24,
659
],
[
659,
24,
1155
]
]
] | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
]
] | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Saxagliptin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Tucatinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Tucatinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Tucatinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib |
DB01118 | DB04845 | 33 | 309 | [
"DDInter76",
"DDInter1001"
] | Amiodarone | Ixabepilone | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286] | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Moderate | 1 | [
[
[
33,
24,
309
]
],
[
[
33,
6,
8374
],
[
8374,
45,
309
]
],
[
[
33,
21,
29269
],
[
29269,
60,
309
]
],
[
[
33,
63,
1419
],
[
1419,
24,
309
]
],
[
[
33,
25,
1619
],
[
1619,
63,
309
]
],
[
[
33,
24,
1434
],
[
1434,
63,
309
]
],
[
[
33,
25,
1487
],
[
1487,
24,
309
]
],
[
[
33,
64,
467
],
[
467,
24,
309
]
],
[
[
33,
24,
973
],
[
973,
24,
309
]
],
[
[
33,
40,
540
],
[
540,
63,
309
]
]
] | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} (Compound) causes {v} (Side Effect)",
"Menopausal symptoms"
],
[
"Menopausal symptoms",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
],
[
"Benznidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
]
] | Amiodarone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Amiodarone (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Ixabepilone (Compound)
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Amiodarone may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Amiodarone may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Amiodarone may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Amiodarone (Compound) resembles Dronedarone (Compound) and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone |
DB06228 | DB11828 | 792 | 1,406 | [
"DDInter1609",
"DDInter1281"
] | Rivaroxaban | Neratinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011. | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
792,
24,
1406
]
],
[
[
792,
63,
392
],
[
392,
24,
1406
]
],
[
[
792,
25,
1421
],
[
1421,
63,
1406
]
],
[
[
792,
24,
1456
],
[
1456,
24,
1406
]
],
[
[
792,
24,
1619
],
[
1619,
63,
1406
]
],
[
[
792,
25,
578
],
[
578,
24,
1406
]
],
[
[
792,
24,
1593
],
[
1593,
25,
1406
]
],
[
[
792,
25,
283
],
[
283,
64,
1406
]
],
[
[
792,
63,
609
],
[
609,
25,
1406
]
],
[
[
792,
64,
697
],
[
697,
25,
1406
]
]
] | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
]
] | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Rivaroxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Rivaroxaban may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Neratinib
Rivaroxaban may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Neratinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Neratinib
Rivaroxaban may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may lead to a major life threatening interaction when taken with Neratinib |
DB01240 | DB11689 | 885 | 321 | [
"DDInter657",
"DDInter1659"
] | Epoprostenol | Selumetinib | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials. Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare, with an estimated incidence of 1/3000 individuals. It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system.[A193533,A193608] Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered relatively uncommon compared to other variants of NF-1. Luckily, the use of selumetinib in patients with NF-1 have shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes. Selumetinib was approved by the FDA on April 10, 2020. It was later approved by Health Canada on August 23, 2022. | Moderate | 1 | [
[
[
885,
24,
321
]
],
[
[
885,
63,
291
],
[
291,
24,
321
]
],
[
[
885,
25,
498
],
[
498,
24,
321
]
],
[
[
885,
25,
1421
],
[
1421,
63,
321
]
],
[
[
885,
24,
235
],
[
235,
24,
321
]
],
[
[
885,
40,
1061
],
[
1061,
24,
321
]
],
[
[
885,
64,
553
],
[
553,
24,
321
]
],
[
[
885,
24,
283
],
[
283,
64,
321
]
],
[
[
885,
63,
291
],
[
291,
24,
298
],
[
298,
24,
321
]
],
[
[
885,
25,
498
],
[
498,
24,
298
],
[
298,
24,
321
]
]
] | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} (Compound) resembles {v} (Compound)",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
],
[
"Protein C",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
],
[
"Protein C",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
]
] | Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Epoprostenol may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Epoprostenol may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Epoprostenol (Compound) resembles Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Epoprostenol may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Selumetinib
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Epoprostenol may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib |
DB09570 | DB10315 | 1,480 | 1,137 | [
"DDInter1002",
"DDInter1127"
] | Ixazomib | Measles virus vaccine live attenuated | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration. | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
1480,
25,
1137
]
],
[
[
1480,
64,
581
],
[
581,
25,
1137
]
],
[
[
1480,
63,
384
],
[
384,
25,
1137
]
],
[
[
1480,
25,
676
],
[
676,
64,
1137
]
],
[
[
1480,
24,
738
],
[
738,
64,
1137
]
],
[
[
1480,
64,
581
],
[
581,
25,
1042
],
[
1042,
24,
1137
]
],
[
[
1480,
63,
384
],
[
384,
64,
617
],
[
617,
24,
1137
]
],
[
[
1480,
63,
1101
],
[
1101,
64,
581
],
[
581,
25,
1137
]
],
[
[
1480,
63,
1184
],
[
1184,
24,
1042
],
[
1042,
24,
1137
]
],
[
[
1480,
25,
676
],
[
676,
64,
1042
],
[
1042,
24,
1137
]
]
] | [
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Measles virus vaccine live attenuated"
]
]
] | Ixazomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Ixazomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Ixazomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated
Ixazomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated |
DB00470 | DB00594 | 530 | 863 | [
"DDInter601",
"DDInter68"
] | Dronabinol | Amiloride | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) | Moderate | 1 | [
[
[
530,
24,
863
]
],
[
[
530,
21,
28645
],
[
28645,
60,
863
]
],
[
[
530,
63,
1648
],
[
1648,
24,
863
]
],
[
[
530,
25,
593
],
[
593,
63,
863
]
],
[
[
530,
24,
401
],
[
401,
63,
863
]
],
[
[
530,
1,
1614
],
[
1614,
24,
863
]
],
[
[
530,
21,
28645
],
[
28645,
60,
1061
],
[
1061,
24,
863
]
],
[
[
530,
21,
28921
],
[
28921,
60,
752
],
[
752,
23,
863
]
],
[
[
530,
21,
29169
],
[
29169,
60,
593
],
[
593,
63,
863
]
],
[
[
530,
21,
28900
],
[
28900,
60,
319
],
[
319,
62,
863
]
]
] | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} (Compound) resembles {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is caused by {v} (Compound)",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Tinnitus"
],
[
"Tinnitus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amoxicillin"
],
[
"Amoxicillin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amiloride"
]
]
] | Dronabinol (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Amiloride (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Dronabinol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Dronabinol (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Treprostinil (Compound) and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Dronabinol (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Amiloride
Dronabinol (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Bupropion (Compound) and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Dronabinol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Amoxicillin (Compound) and Amoxicillin may cause a minor interaction that can limit clinical effects when taken with Amiloride |
DB00095 | DB15699 | 66 | 652 | [
"DDInter623",
"DDInter232"
] | Efalizumab | Brexucabtagene autoleucel | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a potential risk of progressive multifocal leukoencephalopathy (PML). | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor therapy have few treatment options.[A216153, A216158] More recently, chimeric antigen receptor (CAR) T cell therapies have been developed that modify a patient's own T cells using viral transduction to bind to and destroy cancerous cells. These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen. Similar to [axicabtagene ciloleucel], brexucabtagene autoleucel employs a murine anti-CD19 single-chain variable fragment (scFv) linked to internal CD28- and CD3ζ-derived co-stimulatory domains.[A216148, A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in the CAR T cell preparation. Brexucabtagene autoleucel was granted accelerated approval for the treatment of relapsed and refractory MCL by the FDA on July 24, 2020, and is currently available through Kite Pharma Inc. under the tradename TECARTUS. | Moderate | 1 | [
[
[
66,
24,
652
]
],
[
[
66,
24,
259
],
[
259,
24,
652
]
],
[
[
66,
63,
1184
],
[
1184,
24,
652
]
],
[
[
66,
25,
976
],
[
976,
25,
652
]
],
[
[
66,
24,
617
],
[
617,
25,
652
]
],
[
[
66,
63,
581
],
[
581,
25,
652
]
],
[
[
66,
24,
259
],
[
259,
24,
1430
],
[
1430,
24,
652
]
],
[
[
66,
24,
1430
],
[
1430,
63,
259
],
[
259,
24,
652
]
],
[
[
66,
63,
1184
],
[
1184,
24,
259
],
[
259,
24,
652
]
],
[
[
66,
25,
976
],
[
976,
24,
810
],
[
810,
24,
652
]
]
] | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
]
] | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Efalizumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Efalizumab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel |
DB01050 | DB11703 | 848 | 405 | [
"DDInter900",
"DDInter9"
] | Ibuprofen | Acalabrutinib | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of acalabrutinib.[L10241,L42795] Also known as ACP-196, acalabrutinib is also considered a second generation BTK inhibitor because it was rationally designed to be more potent and selective than ibrutinib, theoretically expected to demonstrate fewer adverse effects owing to minimized bystander effects on targets other than BTK. Nevertheless, acalabrutinib was approved under the FDA's accelerated approval pathway, which is based upon overall response rate and faciliates earlier approval of medicines that treat serious conditions or/and that fill an unmet medical need based on a surrogate endpoint. Continued approval for acalabrutinib's currently accepted indication may subsequently be contingent upon ongoing verification and description of clinical benefit in confimatory trials. Furthermore, the FDA granted this medication Priority Review and Breakthrough Therapy designations. It also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. At this time, more than 35 clinical trials across 40 countries with more than 2500 patients are underway or have been completed with regards to further research into better understanding and expanding the therapeutic uses of acalabrutinib . | Major | 2 | [
[
[
848,
25,
405
]
],
[
[
848,
63,
139
],
[
139,
24,
405
]
],
[
[
848,
24,
643
],
[
643,
24,
405
]
],
[
[
848,
24,
1598
],
[
1598,
63,
405
]
],
[
[
848,
62,
1194
],
[
1194,
24,
405
]
],
[
[
848,
23,
286
],
[
286,
24,
405
]
],
[
[
848,
25,
990
],
[
990,
24,
405
]
],
[
[
848,
24,
384
],
[
384,
25,
405
]
],
[
[
848,
64,
126
],
[
126,
25,
405
]
],
[
[
848,
25,
802
],
[
802,
25,
405
]
]
] | [
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
],
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
]
] | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ibuprofen may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Acalabrutinib
Ibuprofen may lead to a major life threatening interaction when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Acalabrutinib
Ibuprofen may lead to a major life threatening interaction when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Acalabrutinib |
DB00331 | DB01324 | 1,645 | 178 | [
"DDInter1164",
"DDInter1490"
] | Metformin | Polythiazide | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes. Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1645,
24,
178
]
],
[
[
1645,
24,
674
],
[
674,
40,
178
]
],
[
[
1645,
21,
28714
],
[
28714,
60,
178
]
],
[
[
1645,
63,
352
],
[
352,
23,
178
]
],
[
[
1645,
24,
126
],
[
126,
23,
178
]
],
[
[
1645,
24,
848
],
[
848,
24,
178
]
],
[
[
1645,
25,
258
],
[
258,
24,
178
]
],
[
[
1645,
25,
1527
],
[
1527,
63,
178
]
],
[
[
1645,
63,
1685
],
[
1685,
24,
178
]
],
[
[
1645,
24,
659
],
[
659,
63,
178
]
]
] | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
]
] | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Metformin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Polythiazide (Compound)
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Polythiazide
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Metformin may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Metformin may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide
Metformin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide |
DB00026 | DB06772 | 1,184 | 310 | [
"DDInter94",
"DDInter259"
] | Anakinra | Cabazitaxel | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Moderate | 1 | [
[
[
1184,
24,
310
]
],
[
[
1184,
24,
973
],
[
973,
24,
310
]
],
[
[
1184,
24,
800
],
[
800,
63,
310
]
],
[
[
1184,
23,
1461
],
[
1461,
24,
310
]
],
[
[
1184,
25,
980
],
[
980,
24,
310
]
],
[
[
1184,
25,
334
],
[
334,
64,
310
]
],
[
[
1184,
25,
1064
],
[
1064,
25,
310
]
],
[
[
1184,
64,
1057
],
[
1057,
25,
310
]
],
[
[
1184,
24,
973
],
[
973,
40,
301
],
[
301,
40,
310
]
],
[
[
1184,
24,
800
],
[
800,
63,
973
],
[
973,
24,
310
]
]
] | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
],
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} (Compound) resembles {v} (Compound)",
"Docetaxel"
],
[
"Docetaxel",
"{u} (Compound) resembles {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
],
[
"Duvelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
]
] | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Anakinra may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Anakinra may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Anakinra may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Cabazitaxel
Anakinra may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Cabazitaxel
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Cabazitaxel
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel (Compound) resembles Docetaxel (Compound) and Docetaxel (Compound) resembles Cabazitaxel (Compound)
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel |
DB00357 | DB04868 | 1,051 | 478 | [
"DDInter71",
"DDInter1293"
] | Aminoglutethimide | Nilotinib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454) | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML. | Moderate | 1 | [
[
[
1051,
24,
478
]
],
[
[
1051,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
478
]
],
[
[
1051,
21,
28762
],
[
28762,
60,
478
]
],
[
[
1051,
24,
1135
],
[
1135,
62,
478
]
],
[
[
1051,
23,
1459
],
[
1459,
62,
478
]
],
[
[
1051,
24,
307
],
[
307,
23,
478
]
],
[
[
1051,
63,
1131
],
[
1131,
24,
478
]
],
[
[
1051,
24,
303
],
[
303,
24,
478
]
],
[
[
1051,
25,
828
],
[
828,
24,
478
]
]
] | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dolutegravir"
],
[
"Dolutegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methysergide"
],
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
]
] | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Aminoglutethimide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Aminoglutethimide may lead to a major life threatening interaction when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib |
DB09075 | DB15233 | 498 | 1,650 | [
"DDInter621",
"DDInter142"
] | Edoxaban | Avapritinib | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020. | Major | 2 | [
[
[
498,
25,
1650
]
],
[
[
498,
64,
1478
],
[
1478,
24,
1650
]
],
[
[
498,
63,
557
],
[
557,
24,
1650
]
],
[
[
498,
25,
1320
],
[
1320,
24,
1650
]
],
[
[
498,
24,
1476
],
[
1476,
24,
1650
]
],
[
[
498,
64,
1512
],
[
1512,
25,
1650
]
],
[
[
498,
25,
1421
],
[
1421,
25,
1650
]
],
[
[
498,
63,
1151
],
[
1151,
25,
1650
]
],
[
[
498,
24,
913
],
[
913,
25,
1650
]
],
[
[
498,
64,
1274
],
[
1274,
37,
1650
]
]
] | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
]
] | Edoxaban may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Edoxaban may lead to a major life threatening interaction when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Edoxaban may lead to a major life threatening interaction when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Avapritinib
Edoxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Avapritinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may lead to a major life threatening interaction when taken with Avapritinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Avapritinib
Edoxaban may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib and Flurbiprofen may lead to a major life threatening interaction when taken with Avapritinib |
DB00687 | DB10343 | 870 | 962 | [
"DDInter747",
"DDInter160"
] | Fludrocortisone | Bacillus calmette-guerin substrain tice live antigen | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
870,
25,
962
]
],
[
[
870,
64,
1057
],
[
1057,
25,
962
]
],
[
[
870,
24,
1213
],
[
1213,
25,
962
]
],
[
[
870,
24,
270
],
[
270,
64,
962
]
],
[
[
870,
1,
1486
],
[
1486,
25,
962
]
],
[
[
870,
63,
663
],
[
663,
25,
962
]
],
[
[
870,
25,
976
],
[
976,
25,
962
]
],
[
[
870,
25,
1259
],
[
1259,
64,
962
]
],
[
[
870,
64,
1057
],
[
1057,
25,
617
],
[
617,
24,
962
]
],
[
[
870,
24,
1213
],
[
1213,
63,
617
],
[
617,
24,
962
]
]
] | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
]
] | Fludrocortisone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Bacillus calmette-guerin substrain tice live antigen |
DB08899 | DB09048 | 129 | 555 | [
"DDInter649",
"DDInter1284"
] | Enzalutamide | Netupitant | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo. | Major | 2 | [
[
[
129,
25,
555
]
],
[
[
129,
63,
1101
],
[
1101,
23,
555
]
],
[
[
129,
25,
466
],
[
466,
62,
555
]
],
[
[
129,
63,
254
],
[
254,
24,
555
]
],
[
[
129,
64,
1409
],
[
1409,
24,
555
]
],
[
[
129,
25,
676
],
[
676,
63,
555
]
],
[
[
129,
24,
98
],
[
98,
63,
555
]
],
[
[
129,
24,
1468
],
[
1468,
24,
555
]
],
[
[
129,
64,
1478
],
[
1478,
25,
555
]
],
[
[
129,
25,
1476
],
[
1476,
64,
555
]
]
] | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Netupitant"
]
]
] | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Enzalutamide may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Netupitant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Enzalutamide may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Enzalutamide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Enzalutamide may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Netupitant
Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Netupitant |
DB06643 | DB06772 | 1,136 | 310 | [
"DDInter500",
"DDInter259"
] | Denosumab | Cabazitaxel | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. Chemically, it consists of 2 heavy and 2 light chains, with each light chain consisting of 215 amino acids and each heavy chain consisting of 448 amino acids with 4 intramolecular disulfides. Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Moderate | 1 | [
[
[
1136,
24,
310
]
],
[
[
1136,
63,
973
],
[
973,
24,
310
]
],
[
[
1136,
24,
351
],
[
351,
63,
310
]
],
[
[
1136,
24,
375
],
[
375,
64,
310
]
],
[
[
1136,
64,
1064
],
[
1064,
25,
310
]
],
[
[
1136,
63,
1057
],
[
1057,
25,
310
]
],
[
[
1136,
24,
908
],
[
908,
25,
310
]
],
[
[
1136,
63,
973
],
[
973,
40,
301
],
[
301,
40,
310
]
],
[
[
1136,
24,
351
],
[
351,
63,
973
],
[
973,
24,
310
]
],
[
[
1136,
63,
896
],
[
896,
24,
973
],
[
973,
24,
310
]
]
] | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} (Compound) resembles {v} (Compound)",
"Docetaxel"
],
[
"Docetaxel",
"{u} (Compound) resembles {v} (Compound)",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
]
] | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Cabazitaxel
Denosumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Cabazitaxel
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Cabazitaxel
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Cabazitaxel
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel (Compound) resembles Docetaxel (Compound) and Docetaxel (Compound) resembles Cabazitaxel (Compound)
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel |
DB00322 | DB00361 | 141 | 134 | [
"DDInter742",
"DDInter1939"
] | Floxuridine | Vinorelbine | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC . It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting . A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug . | Moderate | 1 | [
[
[
141,
24,
134
]
],
[
[
141,
24,
147
],
[
147,
63,
134
]
],
[
[
141,
7,
1843
],
[
1843,
46,
134
]
],
[
[
141,
18,
3166
],
[
3166,
46,
134
]
],
[
[
141,
18,
16896
],
[
16896,
57,
134
]
],
[
[
141,
6,
8569
],
[
8569,
57,
134
]
],
[
[
141,
21,
29434
],
[
29434,
60,
134
]
],
[
[
141,
23,
872
],
[
872,
62,
134
]
],
[
[
141,
62,
1176
],
[
1176,
23,
134
]
],
[
[
141,
63,
599
],
[
599,
24,
134
]
]
] | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} (Compound) upregulates {v} (Gene)",
"PPARD"
],
[
"PPARD",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} (Compound) downregulates {v} (Gene)",
"AURKA"
],
[
"AURKA",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} (Compound) downregulates {v} (Gene)",
"IARS2"
],
[
"IARS2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} (Compound) binds {v} (Gene)",
"TYMS"
],
[
"TYMS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} (Compound) causes {v} (Side Effect)",
"Angina pectoris"
],
[
"Angina pectoris",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
]
]
] | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Floxuridine (Compound) upregulates PPARD (Gene) and PPARD (Gene) is upregulated by Vinorelbine (Compound)
Floxuridine (Compound) downregulates AURKA (Gene) and AURKA (Gene) is upregulated by Vinorelbine (Compound)
Floxuridine (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Vinorelbine (Compound)
Floxuridine (Compound) binds TYMS (Gene) and TYMS (Gene) is downregulated by Vinorelbine (Compound)
Floxuridine (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Vinorelbine (Compound)
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine
Floxuridine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine |
DB00321 | DB09488 | 21 | 103 | [
"DDInter78",
"DDInter23"
] | Amitriptyline | Acrivastine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. | Moderate | 1 | [
[
[
21,
24,
103
]
],
[
[
21,
1,
1405
],
[
1405,
24,
103
]
],
[
[
21,
24,
85
],
[
85,
24,
103
]
],
[
[
21,
35,
1264
],
[
1264,
24,
103
]
],
[
[
21,
25,
1053
],
[
1053,
24,
103
]
],
[
[
21,
63,
701
],
[
701,
24,
103
]
],
[
[
21,
40,
1164
],
[
1164,
24,
103
]
],
[
[
21,
25,
1621
],
[
1621,
25,
103
]
],
[
[
21,
1,
1405
],
[
1405,
63,
85
],
[
85,
24,
103
]
],
[
[
21,
24,
85
],
[
85,
24,
1405
],
[
1405,
24,
103
]
]
] | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
]
] | Amitriptyline (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Amitriptyline (Compound) resembles Doxepin (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Amitriptyline may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Amitriptyline (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Amitriptyline may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Acrivastine
Amitriptyline (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine |
DB04865 | DB06335 | 4 | 761 | [
"DDInter1335",
"DDInter1646"
] | Omacetaxine mepesuccinate | Saxagliptin | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
4,
24,
761
]
],
[
[
4,
24,
1491
],
[
1491,
63,
761
]
],
[
[
4,
63,
1573
],
[
1573,
24,
761
]
],
[
[
4,
25,
283
],
[
283,
63,
761
]
],
[
[
4,
24,
478
],
[
478,
24,
761
]
],
[
[
4,
64,
804
],
[
804,
24,
761
]
],
[
[
4,
63,
1101
],
[
1101,
25,
761
]
],
[
[
4,
24,
1491
],
[
1491,
63,
307
],
[
307,
23,
761
]
],
[
[
4,
63,
1573
],
[
1573,
6,
8374
],
[
8374,
45,
761
]
],
[
[
4,
24,
1296
],
[
1296,
62,
1103
],
[
1103,
23,
761
]
]
] | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfinpyrazone"
],
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Saxagliptin"
]
]
] | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Sulfinpyrazone and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Saxagliptin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saxagliptin (Compound)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Saxagliptin |
DB00214 | DB00916 | 1,028 | 112 | [
"DDInter1836",
"DDInter1202"
] | Torasemide | Metronidazole | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections. | Moderate | 1 | [
[
[
1028,
24,
112
]
],
[
[
1028,
6,
3486
],
[
3486,
45,
112
]
],
[
[
1028,
21,
29310
],
[
29310,
60,
112
]
],
[
[
1028,
24,
11
],
[
11,
23,
112
]
],
[
[
1028,
24,
401
],
[
401,
62,
112
]
],
[
[
1028,
63,
600
],
[
600,
23,
112
]
],
[
[
1028,
25,
57
],
[
57,
62,
112
]
],
[
[
1028,
25,
1166
],
[
1166,
23,
112
]
],
[
[
1028,
24,
1144
],
[
1144,
24,
112
]
],
[
[
1028,
24,
1662
],
[
1662,
63,
112
]
]
] | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} (Compound) causes {v} (Side Effect)",
"Toxic epidermal necrolysis"
],
[
"Toxic epidermal necrolysis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
]
] | Torasemide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Torasemide (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Metronidazole (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Torasemide may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Torasemide may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole |
DB00655 | DB00912 | 559 | 473 | [
"DDInter682",
"DDInter1581"
] | Estrone | Repaglinide | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine. | Moderate | 1 | [
[
[
559,
24,
473
]
],
[
[
559,
6,
1829
],
[
1829,
45,
473
]
],
[
[
559,
21,
28873
],
[
28873,
60,
473
]
],
[
[
559,
24,
609
],
[
609,
63,
473
]
],
[
[
559,
63,
1645
],
[
1645,
24,
473
]
],
[
[
559,
24,
723
],
[
723,
24,
473
]
],
[
[
559,
1,
380
],
[
380,
24,
473
]
],
[
[
559,
1,
890
],
[
890,
63,
473
]
],
[
[
559,
40,
1438
],
[
1438,
24,
473
]
],
[
[
559,
62,
752
],
[
752,
24,
473
]
]
] | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
]
] | Estrone (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Estrone (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Estrone (Compound) resembles Conjugated estrogens (Compound) and Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Estrone (Compound) resembles Mestranol (Compound) and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Estrone (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Estrone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.